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INTRODUCTION
Over the past 30 years, as the expense and complications involved in marketing new drug
entities have increased, with concomitant recognition of the therapeutic advantages of controlled
drug  delivery,  greater  attention  has  been  focused  on development  of  sustained or  controlled
release drug delivery systems. The attractiveness of these dosage forms is due to awareness to
toxicity and ineffectiveness of drugs when administered or applied by conventional method in
the  form  of  tablets,  capsules,  injectables,  ointments  etc.  Usually  conventional  dosage  form
produce wide ranging fluctuation in drug concentration in the blood stream and tissues with
consequent  undesirable  toxicity and poor  efficiency.  This  factors  as  well  as  factors  such  as
repetitive dosing and unpredictable absorption led to the concept  of controlled drug delivery
systems.  The  goal  in  designing  sustained  or  controlled  delivery  systems  is  to  reduce  the
frequency of the dosing or to increase effectiveness of the drug by localization at the site of
action, reducing the dose required or providing uniform drug delivery.  So, controlled release
dosage form is a dosage form that release one or more drugs continuously in a predetermined
pattern for a fixed period of time, either systemically or to a specified target organ. Controlled
release dosage forms provide a better control of plasma drug levels, less dosage frequency, less
side effect, increased efficacy and constant delivery.
            Several types of modified-release drug products are recognized (Leon Shargel et al.,
2004).
Extended-release drug products:  A dosage form that  allows at  least a twofold reduction in
dosage frequency as compared to that drug presented as an immediate-release (conventional)
dosage form. Examples of extended-release dosage forms include controlled-release, sustained-
release, and long-acting drug products. 
Delayed-release drug products: A dosage form that releases a discrete portion or portions of
drug at a time or at times other than promptly after administration, although one portion may be
released  promptly  after  administration.  Enteric-coated  dosage  forms  are  the  most  common
delayed-release products. 
Targeted-release  drug products.  A dosage  form that  releases  drug at  or  near  the  intended
physiologic  site  of  action.  Targeted-release  dosage  forms  may  have  either  immediate-  or
extended-release characteristics.
The term controlled-release drug product was previously used to describe various types
of  oral  extended-release-rate  dosage  forms,  including  sustained-release,  sustained-action,
prolonged-action, long-action, slow-release, and programmed drug delivery. 
1.1. Conventional Drug Delivery System
Pharmaceutical products designed for oral delivery are mainly conventional drug delivery
systems,  which  are  designed  for  immediate  release  of  drug  for  rapid/immediate  absorption
(Robinson, 1987).
           As can be seen in the graph (Figure 1), administration of the conventional dosage form by
extra vascular route does not maintain the drug level in blood for an extended period of time. The
short duration of action is due to the inability of conventional dosage form to control temporal
delivery. 
Fig. 1.   A hypothetical plasma concentration-time profile from conventional multiple dosing and
single  doses  of  sustained  and  controlled  delivery  formulations.  (MSC  =  maximum  safe
concentration, MEC = minimum effective concentration).
The conventional dosage forms like solution; suspension, capsule, tablets and suppository
etc. have some limitations such as
1) Drugs  with  short  half-life  require  frequent  administration,  which  increases  chances  of
missing the dose of drug leading to poor patient compliance.
2) A typical peak-valley plasma concentration-time profile is obtained which makes attainment
of steady state condition difficult.  The unavoidable fluctuations in the drug concentration
may lead to under medication or overmedication as the steady state concentration values fall
or rise beyond the therapeutic range. 
3) The fluctuating drug levels may lead to precipitation of adverse effects especially of a drug
with small therapeutic index, whenever overdosing occurs. 
In  order  to  overcome  the  drawbacks  of  conventional  drug  delivery  systems,  several
technical  advancements have led to the development of controlled drug delivery system that
could revolutionize method of medication and provide a number of therapeutic benefits (Chien,
1992).
1.2. Controlled Release Drug Delivery Systems (CRDDS)
      More precisely, controlled delivery can be defined as
1) Sustained drug action at a predetermined rate by maintaining a relatively constant, effective
drug level in the body with concomitant minimization of undesirable side effects.
2) Localized drug action by spatial placement of a controlled release system adjacent to or in
the diseased tissue. 
3) Targeted drug action by using carriers or chemical derivatives to deliver drug to a particular
target cell type. 
4) Provide a physiologically / therapeutically based drug release system. In other words, the
amount and the rate of drug release are determined by the physiological/ therapeutic needs of
the body. 
A controlled drug delivery system is usually designed to deliver the drug at particular rate.
Safe and effective blood levels are maintained for a period as long as the system continues to
deliver the drug. This predetermined rate  of drug release is  based on the desired therapeutic
concentration and the drug’s pharmacokinetics. 
Advantages of Controlled Drug Delivery System 
1. Overcome patient compliance problems. 
2. Employ less total drug 
a) Minimize or eliminate local side effects
b) Minimize or eliminate systemic side effects 
c) Obtain less potentiation or reduction in drug activity with chronic use.
d) Minimize drug accumulation with chronic dosing. 
3. Improve efficiency in treatment 
a) Cures or controls condition more promptly.
b) Improves control of condition i.e., reduced fluctuation in drug level.
c) Improves bioavailability of some drugs.
d) Make use of special effects, e.g. Sustained-release aspirin for morning relief of arthritis
by dosing before bed time. 
4. Economy i.e. reduction in health care costs. The average cost of treatment over an extended
time period may be less, with lesser frequency of dosing, enhanced therapeutic benefits and
reduced side effects. The time required for health care personnel to dispense and administer
the drug and monitor patient is also reduced. 
Disadvantages
1) Decreased systemic availability in comparison to immediate release conventional  dosage
forms, which may be due to incomplete release, increased first-pass metabolism, increased
instability,  insufficient  residence  time  for  complete  release,  site  specific  absorption,  pH
dependent stability etc. 
2) Poor in vitro – in vivo correlation. 
3) Retrieval of drug is difficult in case of toxicity, poisoning or hypersensitivity reactions. 
4) Reduced potential for dose adjustment of drugs normally administered in varying strengths
(Hoffman, 1998).
1.3. Oral Controlled Drug Delivery Systems 
Oral controlled release drug delivery is a system that provides continuous oral delivery of
drugs at predictable and reproducible kinetics for a predetermined period throughout the course
of GI transit and also the system that target the delivery of a drug to a specific region within the
GI tract for either a local or systemic action (Vora et al., 1996).
Classification of Oral Controlled Release Systems 
A) Diffusion Controlled Systems
I.  Reservoir Devices.
A core of drug (the reservoir) surrounded by a polymeric membrane characterizes them.
The nature of the membrane determines the rate of drug release.
The characteristics of reservoir diffusion systems are
1. Zero order drug release is possible.
2. The drug release rate is dependent on the type of polymer.
3. High molecular weight compounds are difficult to deliver through the device. Coating and
microencapsulation technique can be used to prepare sub devices.
II.  Matrix Devices.
 It consists of drug dispersed homogeneously in a matrix. The characteristics of the matrix
diffusion system is
1. Zero order release cannot be obtained.
2. Easy to produce than reservoir devices.
3. High molecule weight compounds are delivered through the devices.
B) Dissolution controlled systems
I. Matrix Dissolution Controlled System
Aqueous dispersions, congealing, spherical agglomeration etc. can be used.  
II.    Encapsulation Dissolution Control
 Particles, seeds or granules can be coated by technique such as microencapsulation. Pellets
are agglomerates of fine powders or granules of bulk drugs and excipients. They consist of small,
free flowing spherical or semispherical solid units typically from about 0.5-1.5mm.
These are intended usually for oral administration.
Advantages of pellets   
 Pellets are non dusting.
 Dose uniformity and accurate release profile
 Takes up less space because they are compressed.
 The ingredients that make up a pellet do not separate during transit and storage.
 Pellets  also  allow the  separation  of  incompatible  ingredients  with  in  different
layers of the pellet body.
Theory of pellet formation and growth (James Swarbick et al., 1993)
• Nucleation 
• Coalescence
• Layering 
• Abrasion transfer.
Fig  2.  Pellet  growth  mechanism.  (A)  Nucleation,  (B)  coalescence,  (C)  layering  and (D)
abrasion transfer
Methods of preparation of pellets
                                             1. Drug layering.
                                             2. Extrusion and Spheronization.
                                             3. Other pelletization methods
                                                              Globulation
                                                              Agitation
                                                              Compaction.
             Compaction and drug layering are the most widely used pelletization techniques in
pharmaceutical industry. Of the compaction techniques, extrusion and spheronization is the most
popular  method.  Recently,  however,  melt  pelletization  has  been  used  frequently  in  making
compaction pellets using a different type of equipments, eg: High-shear mixer. Other methods of
pelletization  such  as  globulation,  balling  and  compression  are  also  used  in  development  of
pharmaceutical pellets but in a limited scale.
1. Pelletization by Drug Layering (Olsen, K., Ghebre-Sellassie, I 1989)
                 Pelletization by layering is nothing but pellet build-up, layer by layer, around a given
starting core. Pellet diameter may be between 0.6mm and 2.5mm.
       Two types of layering are
a. Powder layering
b. Suspension layering
a. Powder layering
Powder  layering  involves  the  deposition  of  successive  layers  of  dry  powders  of  drugs  and
excipients on preformed nuclei or cores with the help of binding liquids. As powder layering
involves  simultaneous  application  of  binding  agents  and  dry  powders,  hence  it  requires
specialized equipments  like spheronizer.  The primary requirement  in  this  process  is  that  the
product container should be solid walls with no perforation to avoid powder lose beneath the
product chute before the powder is picked off by the wet mass of pellets that is being layered.
                                       Figure 3. Powder layering process 
b. Suspension layering
Solution layering involves the deposition of successive layers of solution and/or suspensions of
drug  substances  and  binder  over  the  starter  non-pareal  seeds,  which  is  an  inert  material  or
crystals or granules of the same drug. In fact the coating process involved in general is applicable
to solution or suspension layering technology. Consequently conventional coating pans, fluidized
beds, centrifugal granulators, wurster coaters have been used successively to manufacture pellets
by this method. The efficiency of the process and the quality of the pellets produced are in part
related to the type of equipment used.
                             Figure 4. Suspension or Solution layering process
With suitable additives pellets can be made into tablets or used to fill capsules. The round shape
is ideal for uniform coating. Pellets are good for automatic dosing.
2.  Pelletization  by  Extrusion  and  Spheronization  (Fu  Jijun  et  al.,  2011
PornsakSriamornsak., et al., 1997)
The process involves first making the extrudes from the powder material and then converting the
extrudes into beads using the spheronizer. The powder material could be any kind of powder
(drug powder, ayurvedic powder, food ingredient powder, detergent powder, nuclear powder etc).
A diagrammatic representation of the entire process is explained in figure No.5.                           
                              
Fig 5. Pelletization by Extrusion and Spheronization.
C)  Diffusion  and Dissolution Controlled System.
      In  a  bioerodible matrix, the drug is homogenously dispersed
in a matrix and it is released either by swelling controlled mechanism or
by  hydrolysis  or  by enzymatic attack.
1.4.  Types  of  Extended- Release Products
 General  approaches to manufacturing an extended-release drug
product  include  the use of  a matrix  structure  in  which  the  drug  is
suspended or dissolved, the use of a rate-controlling membrane through which the drug diffuses,
or a combination of both. Among the many types of commercial preparations available, none
works by a single drug-release mechanism. Most extended-release products release drug by a
combination  of  processes  involving  dissolution,  permeation,  and  diffusion.  The  single  most
important factor is water permeation, without which none of the product release mechanisms
would operate. Controlling the rate of water influx into the product generally dictates the rate at
which the drug dissolves. Once the drug is dissolved, the rate of drug diffusion may be further
controlled to a desirable rate. Table 1 shows some common extended-release product examples
and the  mechanisms for  controlling drug release,  and  lists  the compositions  for  some drugs
(Leon Shargel, 2004).                                       
Table 1.  Examples of Oral Extended-Release Products
Type  Trade Name Rationale
Erosion tablet
 
 
Constant-T Theophylline 
Tenuate Dospan Diethylpropion HCl dispersed in hydrophilic matrix
Tedral SA Combination  product  with  a  slow-erosion
component  (theophylline,  ephedrine  HCl)  and  an
initial-release  component  theophylline,  ephedrine
HCl, phenobarbital)
Waxy matrix tablet Kaon Cl  Slow  release  of  potassium chloride  to  reduce  GI
irritation
Coated  pellets  in
capsule
Ornade spansule Combination  phenylpropanolamine  HCl  and
chlorpheniramine with initial- and extended-release
component
Pellets in tablet Theo-Dur Theophylline 
Leaching
 
Ferro-Gradumet
(Abbott)
Ferrous  sulfate  in  a  porous  plastic  matrix  that  is
excreted in the stool; slow release of iron decreases
GI irritation
Desoxyn
gradumet  tablet
(Abbott)
Methamphetamine  methylacrylate
methylmethacrylate  copolymer,  povidone,
magnesium stearate; the plastic matrix is porous
Coated  ion
exchange
Tussionex Cation ion-exchange resin complex of hydrocodone
and phenyltoloxamine
Flotation–diffusion Valrelease Diazapam
Osmotic delivery
 
Acutrim Phenylpropanolamine HCl (Oros delivery system)
Procardia-XL GITS—gastrointestinal  therapeutic  system  with
NaCl-driven (osmotic pressure) delivery system for
nifedipine 
Microencapsulation
 
 
Bayer  timed-
release
Aspirin
Nitrospan Microencapsulated nitroglycerin 
Micro-K
Extencaps
Potassium chloride microencapsulated particles
1.5. Factors Influencing the Design and Performance of Sustained Release Products
          The type of delivery system and route of administration of the drug presented in sustained
drug delivery system may depend upon two properties (Bramhankar and Jaiswal, 1995). They are
I. Physicochemical Properties of drugs
II. Biological Factors.
I. Physicochemical Properties of Drugs
1. Dose size 
For orally administered systems, there is an upper limit to the bulk size of the dose to be
administered. In general a single dose of 0.5 to 1gm is considered maximum (Nicholas et al.,
1987).
2. Ionization, PKa & Aqueous Solubility 
              The pH Partition hypothesis simply states that the unchanged form of a drug species will
be  preferentially absorbed  through many body tissues.  Therefore it  is  important  to  note the
relationship  between  the PKa of  the  compound  and  its  absorptive  environment.  For  many
compounds, the site of maximum absorption will also be the area in which the drug is least
soluble.
                   For conventional dosage forms the drug can generally fully dissolve in the stomach and
then be absorbed in the alkaline pH of the intestine. For sustained release formulations much of
the drug will arrive in the small intestine in solid form. This means that the solubility of the drug
is likely to change several orders of magnitude during its release.
 Compounds with very low solubility are inherently controlled, since their release over
the time course of a dosage form in the GIT will be limited by dissolution of the drug. The lower
limit for the solubility of a drug to be formulated in a sustained release system has been reported
to be 0.1mg/mL (Fincher et al., 1968). Thus for slightly soluble drugs, diffusional systems will
be poor choice, since the concentration in solution will be low.           
  For example Tetracycline has maximum solubility in the stomach and least     solubility
in the intestine where it is maximally absorbed. Other examples of drugs whose incorporation
into sustained release systems are limited because of their  poor aqueous solubility and slow
dissolution rate are digoxin, warfarrin, griseofulvin and salicylamide. Very soluble drugs are also
good candidates for the sustained release dosage forms. 
3. Partition coefficient    
               The compounds with a relatively high partition coefficient are predominantly lipid
soluble and easily penetrate membranes resulting high bioavailability. Compounds with very low
partition coefficient will have difficulty in penetrating membranes resulting poor bioavailability.
Furthermore partitioning effects apply equally to diffusion through polymer membranes.
4. Drug Stability
               The drugs, which are unstable in stomach, can be placed in a slowly soluble form and
their release delayed until they reach the small intestine. However,  such a strategy would be
detrimental for drugs that either are unstable in the small intestine (or) undergo extensive gut
wall metabolism, as pointed out in the decrease bioavailability of some anticholinergic drugs
from controlled /sustained release formulation. In general the drugs, which are unstable in GIT
environment poor candidates for oral sustained release forms.
    5. Protein Binding 
       It is well known that many drugs bind to plasma proteins with a concomitant influence on
the duration of drug action.  Since blood proteins are mostly recirculated and not eliminated.
Drug  protein  binding  can  serve  as  depot  for  drug  producing  a  prolonged  release  profile,
especially if a high degree of drug binding occurs.
 
II. Biological Factors
1. Biological Half-Life
Therapeutic compounds with half-life less than 8 hrs are excellent candidates for sustained
release preparations. Drugs with very short half-life (less than 2 hrs) will require excessively
large amounts of drug in each dosage unit to maintain controlled effects. Thus forcing the dosage
form itself to become too large to be administered. Compounds with relatively long half-lives,
generally greater than 8 hrs are not used in the sustained release dosage forms, since their effect
is already sustained and also GI transit time is 8-12 hrs (Jantzen et al., 1996). So the drugs, which
have long -half life and short half- life, are poor candidates for sustained release dosage forms.
Some examples  of  drug  with  half-lives  of  less  than  2  hours  are  ampicillin,  cephalexin,
cloxacillin,  furosemide,  levodopa,  penicillin  G and propylthiouracil.  Examples  of  those with
half-lives  of  greater  than  8 hours  are  dicumarol,  diazepam, digitoxin,  digoxin,  guanethidine,
phenytoin and warfarin.
2. Absorption
The characteristics of absorption of a drug can greatly affect its suitability as a sustained
release product. Drugs which are absorbed by specialized transport process (carrier mediated)
and drug absorption at special sites of the gastrointestinal tract (Absorption Window) are poor
candidates for sustained release products.
3. Metabolism
  The metabolic conversion of a drug to another chemical form usually can be considered in
the design of a sustained-release system for that drug. As long as the location, rate and extent of
metabolism are known and the rate constant(s) for the process (es) are not too large, successful
sustained-release products can be developed.         
  There are two factors associated with the metabolism of some drugs; however that present
problems of their use in sustained-release systems. One is the ability of the drug to induce or
inhibit enzyme synthesis; this may result in a fluctuating drug blood level with chronic dosing.
The other is  a  fluctuating drug blood level  due to  intestinal  (or  other  tissue)  metabolism or
through a hepatic first-pass effect.
    Examples  of  drugs  that  are  subject  to  intestinal  metabolism  upon  oral  dosing  are
hydralazine, salicylamide, nitroglycerine, isoproterenol, chlorpromazine and levodopa. Examples
of drugs that undergo extensive first-pass hepatic metabolism are propoxyphene, nortriptyline,
phenacetine, propranolol and lidocaine.
           Drugs that are significantly metabolized especially in the region of the small intestine can
show decreased bioavailability from slower releasing dosage forms. This is due to saturation of
intestinal wall enzyme systems. The drugs should not have intestinal first pass effect and should
not  induce  (or)  inhibit  metabolism  are  good  candidates  for  sustained  release  dosage  forms.
Various technologies used for controlled release drug delivery systems were given in Table 2
(Chien et al., 1990).
Table 2. Technologies used for CRDDS 
S.NO. DESIGN  OR  TYPE  OF  THE
SYSTEM
RELEASE MECHANISM
1 Dissolution Controlled CR systems
• Encapsulation (including   Micro
encapsulation)
       - Barrier coating
       - Embedment into a matrix of fatty
materials)                                    
       - Repeat action coatings
       -  Coated  plastic  materials  or
hydrophilic materials
• Matrix Dissolution Control 
The dissolution of drug from system
2
Diffusion Controlled CR systems
• Reservoir  Devices  (Fatty
The diffusion of the drug solution through
polymer coated systems)
• Matrix  Devices  (Fatty  polymer
dispersed systems)      
film
3 Dissolution  and  Diffusion  Controlled
CR systems 
• Non  disintegrating  polymeric
matrix
• Hydrophilic matrices 
Diffusion  of  a  drug  solution  through  a
porous matrix
4
Ion- Exchange Resin CR Systems
Ion-  Exchange  between  the  resin  -  drug
complex and  ions in the GI tract
5
pH - Independent formulations
Influenced  by  change  in  pH  and  ionic
permeability of the membrane coating
6 Osmotically Controlled CR systems
They  contain  the  buffering  agents  in  a
system  which  maintains  constant  pH
throughout  the  GIT,  so  the  drug  release
from the device is not affected by variable
pH  of  GIT.  Water  entering  by  Osmosis
dissolves the drug,  and the drug solution
is forced out through a laser drilled orifice
7 Altered - Density systems Diffusion  from high  -  density  pellets  or
from floating
1.6. Monolithic Matrix System 
In pharmaceutical CRDDS, matrix based systems are the most commonly used type of
release controlling methodology owing to their simple manufacturing process. The preparation of
a tablet with the matrix involves the direct compression of the blends of drug, release retardant
and other additives, in which the drug is uniformly distribute throughout the matrix core of the
release retardant. Alternatively, drug-release retardant blends may be granulated to make the mix
suitable for the preparation of tablets by wet granulation or beads (Colombo et al., 1993).
  To  characterize  and  define  the  matrix  systems  the  following  properties  of  the  matrix  are
considered.
1. Chemical nature of the support.
2. The physical state of the drug.
3. The matrix and alteration in volume as the function of the time.
4. The routes of administration.
5. The  release  kinetics  model  (in  accordance  with  Higuchi’s  equation,  these  system
considered to release the drug as a function of square root of time).  
The classification of the matrix-based systems is based on the following criteria.
• Matrix structure
• Release kinetics
• Controlled release properties (diffusion, erosion and swelling).
• Chemical nature and the properties of the applied release retardant(s). 
Based on the chemical nature of the release retardant(s),  the matrix systems are classified as
given in Table 3.\
Table 3. Classification of Matrix Systems.
Type of the Matrix System Mechanism
Hydrophilic
- Unlimited swelling delivery by diffusion
- Limited swelling controlled delivery
eg:  Hydroxyethylcellulose,  Hydroxypropylmethyl
cellulose
Inert - Inert in nature
- Controlled delivery by diffusion
eg: Ethylcellulose
Lipidic - Delivery by diffusion & erosion
eg: Carnauba wax.
Biodegradable - Non lipidic nature
- Controlled delivery by surface erosion
Resin Matrices - Drug release from drug-resin complex
eg: Ion exchange resins
1.7. Mechanism of Drug Release from Matrix Tablets
.        As shown in Figure 2, in erodible matrices, polymer erosion from the surface of the matrix
determines the drug release; whilst in hydrophilic matrices, formation of the gel layer and its
dynamics  as  a  function  of  time  determines  the  drug  release.  Gel  layer  thickness,  which
determines  the  diffusion  path  length  of  the  drug,  corresponds  to  the  distance  between  the
diffusion and erosion fronts. As the swelling process proceeds, the gel layer gradually becomes
thicker,  resulting  in  progressively  slower  drug-release  rates;  however,  due  to  continuous
hydration,  polymer  disentanglement  occurs  from  the  surface  of  the  matrix,  resulting  in  a
gradually decreasing depletion zone and an increased dissolution rate.
Fig.6. Schematic drug release from matrix diffusion controlled-release drug delivery systems
with the drug homogenously dispersed in: (a) an erodible polymer matrix; and (b) a hydrophilic,
sellable polymer matrix.
1.8. Drug Release Kinetics -Model Fitting of the Dissolution Data
             Whenever a new solid dosage form is developed or produced, it is necessary to ensure
that  drug  dissolution  occurs  in  an  appropriate  manner.  The  pharmaceutical  industry and  the
registration authorities do focus, nowadays, on drug dissolution studies. Drug dissolution from
solid dosage forms has been described by kinetic models in which the dissolved amount of drug
(Q) is a function of the test time, t or Q=f(t). Some analytical definitions of the Q(t) function are
commonly used, such as zero order, first order, Hixson–Crowell, Higuchi, Korsmeyer–Peppas
models. (Mulye and Turco, 1995; Colombo et al., 1999; Kim et al., 1997; Manthena et al., 2004;
Desai et al., 1996; Higuchi  et al., 1963).Different models expressing drug release kinetics were
given in Table 4 
 Zero order kinetics
Q1 = Q0 +K0t
where Q1 is the amount of drug dissolved in time t, Q0 is the initial amount of drug in the solution
(most times, Q0=0) and K0 is the zero order release constant. 
ft = K0 t
where ft = 1-(Wt/W0) and ft represents the fraction of drug dissolved in time t and K0 the apparent
dissolution rate  constant  or  zero  order  release  constant.  In  this  way,  a  graphic  of  the drug-
dissolved  fraction  versus  time  will  be  linear  if  the  previously  established  conditions  were
fulfilled.
Use: This relation can be used to describe the drug dissolution of several  types of modified
release pharmaceutical dosage forms, as in the case of some transdermal systems, as well as
matrix tablets with low soluble drugs, coated forms, osmotic systems, etc. The pharmaceutical
dosage forms following this profile release the same amount of drug by unit of time and it is the
ideal method of drug release in order to achieve a pharmacological prolonged action. 
 First order kinetics
 Kinetic equation for the first order release is as follows
Log Qt = log Q0 + K1t/2.303
where Qt is the amount of drug released in time t, Q0 is the initial amount of drug in the solution
and K1 is the first order release constant. In this way a graphic of the decimal logarithm of the
released amount of drug versus time will be linear. 
The pharmaceutical  dosage forms following this dissolution profile,  such as those containing
water-soluble drugs  in porous matrices,  release the drug in a way that  is  proportional  to the
amount of drug remaining in its interior, in such way, that the amount of drug released by unit of
time diminishes.
 Higuchi model   
                                                        ft = KH t1/2
Where  KH is  the  Higuchi  dissolution  constant  treated  sometimes  in  a  different  manner  by
different authors and theories. Higuchi describes drug release as a diffusion process based in the
Fick’s law, square root time dependent. This relation can be used to describe the drug dissolution
from several  types of modified release pharmaceutical  dosage forms, as in the case of some
transdermal systems and matrix tablets with water-soluble drugs.
 Hixson–Crowell model
Hixson and Crowell (1931) recognizing that the particle regular area is proportional to the cubic
root of its volume derived an equation that can be described in the following manner
W0 1/3-Wt 1/3 = Kst
where W0 is the initial amount of drug in the pharmaceutical dosage form, Wt is the remaining
amount of drug in the pharmaceutical dosage form at time t and Ks is a constant incorporating the
surface–volume relation. This expression applies to pharmaceutical dosage form such as tablets,
where  the  dissolution  occurs  in  planes  that  are  parallel  to  the  drug  surface  if  the  tablet
dimensions diminish proportionally,  in such a manner that the initial geometrical form keeps
constant all the time.          
           A graphic of the cubic root of the unreleased fraction of drug versus time will be linear if
the equilibrium conditions are not reached and if the geometrical shape of the pharmaceutical
dosage form diminishes  proportionally over  time.  This  model  has  been used to describe the
release  profile  keeping  in  mind  the  diminishing  surface  of  the  drug  particles  during  the
dissolution.
Mechanism of Drug Release    
                To find out the drug release mechanism due to swelling (upon hydration) along with
gradual erosion of the matrix, first 60% drug release data can be fitted in 
Korsmeyer–Peppas  model  which  is  often  used  to  describe  the  drug  release  behavior  from
polymeric systems when the  mechanism is  not  well-known or  when more  than one type  of
release phenomena is involved (Korsmeyer et al., 1983).
                                         Log (Mt / M∞) = Log KKP + n Log t                                                   
              where, Mt is the amount of drug release at time t, M∞ is the amount of drug release after
infinite  time,  KKP is  a  release  rate  constant  incorporating  structural  and  geometrical
characteristics of the tablet, and n is the release exponent indicative of the mechanism of drug
release. 
Table 4.  Drug Release Kinetics
Kinetic Model Relation Systems  Following  the
Model
First order ln Qt = ln Qo + Kt
(release is proportional to amount of drug
remaining)
Water-soluble  drugs  in
porous matrix
Zero order ft = Kot
(independent of drug concentration)
Transdermal systems
Osmotic systems
Higuchi ft = KHt1/2
(proportional to square root of time)
Matrix formulations
Hixson-Crowell Wo 1/3 – Wt 1/3 = Kst Erodible  isometric
matrices
ft = fraction of dose release at time ‘t’; 
KH, Ko, and Ks = release rate constants characteristic to respective models; 
Qo = the drug amounts remaining to be released at zero hour; 
Qt = the drug amounts remaining to be released at time ‘t’; 
Wo = initial amount of drug present in the matrix; 
Wt = amount of drug released at time ‘t’.
1.9. Introduction to Hypertension
Blood pressure is the force of blood pushing against blood vessel walls. The heart pumps
blood into the arteries (blood vessels), which carry the blood throughout the body. High blood
pressure, also called hypertension, is dangerous because it makes the heart work harder to pump
blood  to  the  body and  it  contributes  to  hardening  of  the  arteries  or  atherosclerosis  and  the
development of heart failure.
   Hypertension,  also  referred  to  as  high  blood  pressure,  HTN or  HPN,  is  a  medical
condition in which the blood pressure is chronically elevated. 
     There are several categories of blood pressure, including
• Normal: 120/80 mm of Hg
• Prehypertension: 120-139/80-89 mm of Hg
• Stage 1 hypertension: 140-159/90-99 mm of Hg
• Stage 2 hypertension: 160 and above/100 and above 
Hypertension can be classified either essential (primary) or secondary. 
Essential hypertension indicates that no specific medical cause can be found to explain a patient's
condition.  Secondary hypertension indicates  that  the high blood pressure is  a  result  of  (i.e.,
secondary to) another condition, such as kidney disease or tumors. 
The mechanisms and causes of hypertension
The direct mechanisms causing hypertension is one or more of these factors
• An increased tension in the blood vessel walls.
• An increased blood volume caused by elevated levels of salt and lipids in
the blood holding back water.
• Hardened and inelastic blood vessels caused by arteriosclerosis.
• The primary causes behind these mechanisms are not fully understood, but these factors
contribute to causing hypertension
• A high consume of salt
• A high fat consume.
• Stress at work and in the daily life.
• Smoking.
• Over-weight
• Lack of exercise.
• Kidney failure.
Lifestyle measures to prevent and treat hypertension
Lifestyle measures shall always be a component of the hypertension treatment. Sometimes such
measures are enough to cure the condition. Those measures are
• Reducing salt consume.
• Reduction of fat consume, and especially of saturated fat consume.
• Weight reduction.
• Relaxing and stress reduction techniques, for example meditation and autogenic training.
• Regular exercise.
Special food types that reduce the blood pressure
Research projects suggest that the following food types reduce blood pressure.
•  Fish oil and fat fish. The working substances seem to be the omega-3 unsaturated fatty
acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The effect  from
fish oil seems to cease when the fish oil supplements are stopped.
• Olive oil, especially olive oil of the quality extra virgin.
Natural supplements to help against hypertension
            Natural supplements to treat hypertension exist. These supplements reduce blood pressure
by lowering the cholesterol  and lipid content  in the blood, by preventing oxidation of tissue
components  by  free  radicals,  and  by helping  damaged  blood  vessels  to  heal.
Examples of ingredients having these effects are vitamin B3, inositol, turmenic extract and gum
extract.
They  may  also  contain  Ingredients  giving  a  direct  anti-hypertensive  effect,  like
potassium, magnesium, calcium, vitamin C and fatty acids from marine sources.
Medical treatment of hypertension 
           When lifestyle measures and supplements are not enough to cure the condition, medical
treatment must be applied. Many different types of drugs are used, alone or in combination with
other drugs, to treat high blood pressure. The major categories are
• Angiotensin-converting Enzyme (ACE) Inhibitors: ACE inhibitors work by preventing
a  chemical  in  the  blood,  angiotensin  I,  from  being  converted  into  a  substance  that
increases salt and water retention in the body. These drugs also make blood vessels relax,
which further reduces blood pressure. 
• Angiotensin II Receptor Antagonists: These drugs act at a later step in the same process
that ACE inhibitors affect. Like ACE inhibitors, they lower blood pressure by relaxing
blood vessels. 
• Beta blockers: Beta blockers affect the body's response to certain nerve impulses. This,
in  turn,  decreases  the  force  and  rate  of  the  heart's  contractions,  which  lowers  blood
pressure. 
• Blood Vessel  Dilators  (Vasodilators): These drugs  lower blood pressure by relaxing
muscles in the blood vessel walls. 
• Calcium Channel Blockers: Drugs in this group slow the movement of calcium into the
cells of blood vessels. This relaxes the blood vessels and lowers blood pressure. 
• Diuretics: These drugs control blood pressure by eliminating excess salt and water from
the body. 
• Nerve Blockers: These drugs control nerve impulses along certain nerve pathways. This
allows blood vessels to relax and lowers blood pressure. 
REVIEW OF LITERATURE
Madhusudan Rao Yamsani et al.,  (2011) studied the effect of hydrophilic cellulosic
polymers to control the release profile of the Eplerenone and he was the first one who studied the
prolonged drug release profile of Eplerenone. He has prepared matrix mini tablets containing
cellulose polymers like HPMC K4M, HPMC K15M, were prepared by wet granulation technique
using PVP K60 as a tablet binder. The optimized formulation contains 1: 1 ratio (drug to HPMC
K4M ratio) and contains 1:0.7 ratio (drug and HPMC K15M) respectively. The in vitro release
kinetic studies of prepared matrix mini tablets with both the polymers revealed that the amount
of Eplerenone released from the matrix mini tablets at different time intervals were matched with
theoretical release profile of drug for a period of 12 h.
           Hiremath and Saha (2008) have formulated hydrophilic controlled release matrix tablets
of  rifampicin,  a  poorly soluble drug,  using hydroxypropyl  methylcellulose (HPMC) polymer
(low,  medium,  and  high  viscosity)  by  direct  compression  method.  Influence  of  formulation
variables and process parameters such as drug : HPMC ratio, viscosity grade of HPMC, drug
particle size, and compression force on the formulation characters and drug release has been
studied. Their results indicated that the release rate of the drug and the mechanism of release
from the HPMC matrices are mainly controlled by the drug:HPMC ratio and viscosity grade of
the HPMC. In  general,  decrease in the drug particle  size decreased the drug release.  Lower
viscosity HPMC polymer was found to be more sensitive to the effect of compression force than
the higher viscosity.
           Ravi  et  al.,  (2008)  have designed oral  controlled release (CR)  matrix  tablets  of
zidovudine (AZT) using HPMC, EC and cabopol-971P (CP) and studied the effect of various
formulation factors on in vitro drug release. . Release rate decreased with increase in polymer
proportion and compression force. The release rate was lesser in formulations prepared using CP
(20%) as compared to HPMC (20%) as compared to EC (20%). No significant difference was
observed in the effect of pH of dissolution media on drug release from formulations prepared
using HPMC or EC, but significant difference was observed in CP based formulations. Decrease
in agitation speed from 100 to 50 rpm decreased release rate from HPMC and CP formulations
but no significant difference was observed in EC formulations. Mechanism of release was found
to be dependent predominantly on diffusion of drug through the matrix than polymer relaxation
incase of HPMC and EC formulations, while polymer relaxation had a dominating influence on
drug release than diffusion incase of CP formulations. Designed CR tablets have shown an initial
release of 17-25% in first hour and extending the release up to 16-20 hours.
Roberts et al.,  (2007)  have studied the release profiles of aspirin  from hypromellose
matrices in hydro-ethanolic media. Percent aspirin released increased with increasing levels of
ethanol in the dissolution media, correlating with the drug's solubility, however, dose dumping of
aspirin did not occur. An initial rapid release was observed in media comprising 40% ethanol.
Release in these conditions was considered to be both erosion and diffusion-mediated, in contrast
to the release in 0, 10, 20 and 30% ethanol media, where erosion-controlled release dominated.
Image analysis  of  matrix  swelling indicated a  slower initial  interaction between ethanol  and
Hypromellose accounting for the initial rapid release. Cloud point studies suggested that ethanol
retarded hydration of the polymer. 
             Sinju et al., (2004) have described the effects of temperature and humidity on tablets
containing kollidon® SR using diphenhydramine HCl as a model drug. Exposure of tablets to
accelerated stability condition (40°C/75%RH) in an open dish resulted in rapid increases in tablet
hardness, accompanied by step-wise decreases in dissolution rate.  But exposure to 25°C/60%RH
similarly resulted in increases in tablet hardness, although with minimal impact on dissolution.
Exposure of kollidon® SR tablets to the aqueous coating process indeed resulted in noticeable
changes in both hardness and dissolution. Application of the opadry solution appears to affect
tablet behavior to a lesser degree, compared to water, most likely due to protection via formed
barrier  film. Therefore the authors  concluded that  attention needs  to  be paid to  the extreme
sensitivity  of  kollidon® SR  matrix  tablets  to  temperature  and  moisture  during  product
development.  
Ghali, Gazzaniga et al. (1998) Extrusion-spheronisation is a multiple-step compaction process
comprising dry mixingof the ingredients with excipients, wet granulation of the mass, extrusion
of the wetted mass, charging the extrudates into the spheroniser to produce a spherical shape,
drying the wet pellets in a dryer and, finally, screening to achieve the required size distribution
The granulation step can be performed both in batch-type processors, including a conventional
planetary  mixer,  and  in  vertical  or  horizontal  high-shear  and  sigma-blade  mixers   and  in
continuous mixers, such as Nica M6 instant (Hellén 1992), and high-shear twin-screw mixer-
extruders
Jackson, Mohammed Nastruzzi et al., (1989). The layering process comprises the deposition
of successive layers of drug entities from solution, suspension or dry powder on nuclei which
may be crystals or granules of the same material or inert starter seeds. In solution/suspension
layering, drug particles are dissolved or suspended in the binding liquid. In powder layering,
complete dissolution does not occur, due to low liquid saturation, irrespective of the solubility of
the active agent in the binding liquid. In powder drug layering, a binder solution is first sprayed
onto the previously prepared inert seeds, followed by the addition of powder Conventional pan
coaters have been used from the very beginning of the history of drug layering pelletization.
From  the  economic  point  of  view,  however,  use  of  conventional  pan  coaters  is  not  very
reasonable due to the higher labor costs and time consumption, and lower yield
Sastry  and  Fuerstenau  (1972)  In  order  to  judiciously  select  and  optimise  any
pelletization/granulation process, it is important to understand the fundamental mechanisms of
granule formation and growth. Different theories have been postulated related to the mechanism
of formation and growth of pellets. Some of these theories are derived from experimental results
while others are confined to visual observations. Results obtained from the experiments with
some form of tracer technique are regarded as acceptable and convincing. As the conventional
granulation the most thoroughly studied, most classified pelletization process, which involves a
rotating drum, a  pan or  a  disc,  has  been  divided  into  three  consequtive regions:  nucleation,
transition  and ball  growth.  However,  based  on  the  experiments  on  the  mechanism of  pellet
formation and growth, the following steps were proposed: nucleation, coalescence, layering and
abrasion transfer.
Scope of Work
Eplerenone is a highly selective aldosterone receptor antagonist (SARA) to effectively block
aldosterone at  receptor sites  in  body tissues  (Spertus  J.A.et  al.,  2002).  Aldosterone plays  an
important role in chronic heart failure, even when other rennin–angiotensin–aldosterone system
(RAAS)-inhibiting agents are used (Stier C.T, 2002, Staessen S.,1981). Eplerenone is used for
treatment of hypertension and heart failure. Eplerenone is a steroid nucleus- based antimineral
corticoid that is chemically and enzymatically interconvertible to an open lactone ring form. It is
rapidly  and  nearly  completely  absorbed  from the  gastrointestinal  tract  (GIT)  following  oral
ingestion, showing 69% bioavailability. Detectable plasma levels occur within one-half hour and
peak plasma levels occur in about 1-2 hours and the plasma half-life is 4 hours. In the treatment
of hypertension the usual initial dosage is 25 mg once daily, whether used alone or added to
diuretic therapy.  Dosage  may be  increased  or  decreased  depending  on  heart  rate and  blood
pressure response. The usual total maintenance dosage is 50-100 mg per day. 
             Although conventional tablets of Epelerenone are available in the market commercially,
no  study  has  been  done  so  far  for  preparing  the  Epelerenone  sustained-release  tablets.  To
improve the oral bioavailability and to reduce the dose dependent toxicity there is a need for the
development of sustained-release formulations (Gregory et al., 2004; Mandana et al., 2000).
The most commonly used method of modulating the drug release is to include it in a
matrix system (Salsa et al., 1997).An effort was therefore made to develop simple and effective
sustained-release Epelerenone tablets using a polymer matrix system in multi unit particles. The
drug is slightly soluble in water and hence judicious selection of matrix layer formation over a
dump mass of the drug is essential for achieving constant release. HPMC is the most commonly
and successfully used hydrophilic binding agent,  pore forming agent along with hydrophobic
polymer system for the preparation of oral controlled drug delivery systems (Colombo et al,,
1993).Upon contact  with  the gastrointestinal  fluid,  HPMC swells,  gels,  and finally dissolves
slowly (Siepmann et al., 1999). The pores formed in the matrix layer acting as a barrier to both
the influx of water and the efflux of the drug in solution (Colombo et al., 2000; Kiil and Dam.
2003). As the proportion of the hydrophobic polymer in the formulation increases, the gel formed
is more likely to diminish the diffusion of the drug and delay the erosion of the matrix (Ford et
al., 1985). The dissolution can be either disentanglement or diffusion controlled depending on
the molecular weight and thickness of the diffusion boundary layer. The rate of polymer erosion
and pore formation in the release retarding layer as well as the corresponding rate of drug release
are found to increase with either higher levels of drug loading (Narasimhan and Peppas.,1997).
However, the use of hydrophilic pore former alone for sustaining drug release for highly water
soluble drugs is restricted due to rapid diffusion of the dissolved drug through the hydrophilic gel
network but for the drugs like Eplerenone we can use as it is or in combination with hydrophobic
polymers (Liu et al., 2001). 
Hence, in the present study, an attempt has been made to develop the sustained-release
multi unit particles in tablets of Eplerenone using hydrophobic ethyl cellulose and two other
commercial aqueous dispersions of ethyl cellulose, and the sustained pattern of Eplerenone was
evaluated by in-vitro drug release for 12 hours. The drug release data were plotted using various
kinetic equations (zero-order, first-order, Higuchi’s kinetics, Korsmeyer’s equation, and Hixson-
Crowell  cube  root  law)  to  evaluate  the  drug  release  mechanism and  kinetics.  In-vivo  drug
release, biopharmaceutical evaluation, and in-vitro/in-vivo correlations were beyond the scope of
this study and will be considered in future work.
Objective
 The present work is aimed at preparing and evaluating sustained-release tablets (MUPS)
of Eplerenone using different cellulosic polymers 
 To study the effect of nature of different cellulosic polymers in different concentrations
on the rate of drug release.
 Plan of Work
 Construction of the calibration curve for Epelerenone in 0.1N HCl and 6.8 pH
phosphate buffer.
 Calculation of the dose and to construct theoretical release profile of Eplerenone
from sustained –release formulations.
Preparation of Sustained release pellets using different cellulosic polymers,
a) Ethyl cellulose
b) Surelease
c) Aquacoat ARC
 Evaluation of prepared pellets and Precompression blend and prepared tablets.
 Selection of the best batch of tablets based on the in-vitro release studies.
 Preparation of tablets by direct compression method using the final selected batch
of pellets and evaluation of the tablets.
 To perform swelling and erosion studies, FTIR studies, and stability studies for
the optimized tablet formulation.
Drug profile
1. Description
Nomenclature
Generic Name : Eplerenone
Chemical name : Methyl hydrogen 9, 11- epoxy-17- hydroxy-3- xopregn-4-ene-7, 21-
dicarboxylate, γ-lactone
Formula
Empirical formula : C24H30O6 
Chemical structure :
Physical and Chemical Properties
Molecular weight : 414.49
Description : Eplerenone is an odorless, white to off-white crystalline  Powder
Melting point : 241-243°C
Solubility : It is very slightly soluble in water, with its Solubility essentially pH 
independent.
2. Pharmacokinetics
Bioavailability : 69%
Half-life : 4-6 hrs
Apparent Volume of distribution : 66.5 L
BCS Class : Class II
Clearance : 10 L/hr.
Partition coefficient : 7.1 at pH 7.0.
Calculated dose : 70mg
3. Pharmacology
i)   Indications and Dosage 
For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection
fraction  <40%)  and  clinical  evidence  of  congestive  heart  failure  after  an  acute  myocardial
infarction. The usual initial dosage of Eplerenone is 25 mg once a day. Dosage may be increased
or decreased depending on heart rate and blood pressure response.
iii) Mechanism of Action
 Eplerenone  binds  to  the  mineralocorticoid  receptor  and  thereby  blocks  the  binding  of
aldosterone  (component  of  the  renin-angiotensin-aldosterone-system,  or  RAAS).  Aldosterone
synthesis,  which  occurs  primarily  in  the  adrenal  gland,  is  modulated  by  multiple  factors,
including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH)
and potassium. Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g., kidney)
and nonepithelial  (e.g.,  heart,  blood vessels,  and  brain)  tissues  and  increases  blood pressure
through induction of sodium reabsorption and possibly other mechanisms.
iv) Drug Interactions
       Eplerenone has some interactions with the drugs like itraconazole, the concomitant use
of the CYP3A4 potent inhibitors ketoconazoleand itraconazole is contraindicated
v) Adverse Effects
        Common adverse drug reactions (ADRs) associated with the use of eplerenone include:
hyperkalaemia, hypotension,  dizziness,  altered  renal  function,  and  increased  creatinine
concentration (Rossi S, 2006). Eplerenone, may have a lower incidence of sexual side effects
such as feminization,  gynecomastia,  impotence,  low sex drive and reduction of size of male
genitalia. (Craft, Jennifer, 2004)
vi) Toxicity
The most likely symptoms of human overdosage would be anticipated to be hypotension or
hyperkalemia. However, no cases of human overdosage with eplerenone have been reported.
4.  Pharmacodynamics
Eplerenone,  an aldosterone  receptor  antagonist  similar  to  spironolactone,  has  been shown to
produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of
the  negative  regulatory  feedback  of  aldosterone  on  renin  secretion.  The  resulting  increased
plasma  renin  activity  and  aldosterone  circulating  levels  do  not  overcome  the  effects  of
eplerenone.  Eplerenone  selectively  binds  to  recombinant  human  mineralocorticoid  receptors
relative  to  its  binding  to  recombinant  human  glucocorticoid,  progesterone  and  androgen
receptors.
5. Method of analysis
• Spectroscopy like-IR, NMR, Mass and UV-Visible Spectroscopy.
• Thin Layer Chromatography
• High Performance Liquid Chromatography
6. Storage
Store at USP control room temperature 20° to 25°C (68° to 77°F) & protected from light.
Dispense in a well-closed, light-resistant container.
Excipients Profile
1. Hypromellose
Hypromellose is a partly O-methylated and O-(2- hydroxypropylated) cellulose.
Synonyms           :      Benecel  MHPC;  Hydroxypropylmethylcellulose  (HPMC);
Methocel; Metolose; Tylopur.
Description          :     Odorless  and  tasteless,  white  or  creamy-white  fibrous  or
granular powder.
Grades                :       Methocel 5cps, Methocel 6cps, Methocel K100 Premium LVEP, Methocel
K4M, K15M, K100M, Metolose 60SH, 65SH, 90SH.
Stability                       :           Stable material, although it is hygroscopic after drying.
Acidity/alkalinity         :          pH = 5.5–8.0 for a 1% w/w aqueous solution
Density (true)               :          1.326 g/cm3.
Melting point               :         Browns at 190–200°C; chars at 225–230°C. Glass transition
temperature is 170–180°C.
Viscosity                      :         Ranges from 3-100000 mPa s.
                                    Methocel K100M (100000 mPa s), 
                                    Methocel  K15M (15000 mPa s),
                                    Methocel K4M (4000 mPa s).
Safety                           :       Non-toxic and non-irritant material, although excessive oral
consumption may have a laxative effect.
Uses                             :       As a binder (2% - 5% w/w),
                                             Matrix former (10% - 80% w/w),
                                             Thickening agent (0.45% - 1% w/w),
                                          It is also used as an emulsifier, suspending agent, and stabilizing 
agent in topical gels and ointments.
2. Ethylcellulose
Ethylcellulose, an ethyl ether of cellulose, is a long-chain polymer of β-anhydroglucose units 
joined together by acetal linkages.
Synonyms                   :        Aquacoat ECD; Aqualon; E462; Ethocel; Surelease, Aquacoat ARC.
Description                 :        It is a tasteless, free-flowing, and white to light tan-colored powder.
Functional Category   :       Coating agent; flavoring fixative; tablet binder; tablet filler;     
viscosity-increasing agent.
Solubility              :      It is practically insoluble in glycerin, propylene glycol, and water.
Ethylcellulose that contains less than 46.5% of ethoxyl groups is freely
soluble  in  chloroform,  methyl  acetate,  and  tetrahydrofuran,  and  in
mixtures  of  aromatic  hydrocarbons  with  ethanol  (95%).Ethylcellulose
that contains not less than 46.5% of ethoxyl groups is freely soluble in
chloroform, ethanol (95%), ethyl acetate, methanol, and toluene.
Density (bulk)            :     0.4 g/cm3
Viscosity                    :     7 to 100 mPa s
 Stability and Storage     :    It is a stable, slightly hygroscopic material. It should be stored at a
temperature not exceeding 32°C (90°F) in a dry area away from all
sources of heat. It should not be stored next to peroxides or other
oxidizing agents.
Safety                   :   It is generally regarded as a nontoxic, nonallergenic, and nonirritating
material. It is not metabolized following oral consumption and is
therefore a noncalorific substance.
Uses                                  :      It is used in the microencapsulation (10-20% w/w).
                                        As a sustained-release tablet coating (3-20% w/w).
                                        It can be used for tablet coating and tablet granulation 
                                        (1- 3% w/w).
3. Microcrystalline cellulose
Microcrystalline cellulose is purified, partially depolymerized cellulose.
   Synonyms                        :      Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline 
cellulose; E460; Emcocel; Ethispheres; Fibrocel; Pharmacel; 
Tabulose; Vivapur.
Description                  :      It occurs as a white, odorless, tasteless, crystalline powder composed
of porous particles.
Grades                         :       Avicel PH-101, PH-102, PH-103; Emcocel 50M,  90M; Vivapur 
101, 102.
Functional  Category:       Adsorbent;  suspending agent;  tablet  and capsule diluent;  tablet
disintegrant & Cushioning agent.
Solubility                     :       Slightly soluble in 5% w/v sodium hydroxide solution;     practically
insoluble in water, dilute acids, and most organic solvents.
Melting point                :     Chars at 260-270°C.
Stability and Storage    :     It is a stable though hygroscopic material. The bulk material should 
be stored in a well-closed container in a cool, dry place.
Safety                            :      It is a relatively nontoxic and nonirritant material.
Uses                               :     It is widely used as a diluent (20 – 90 %w/w).
                                             As a tablet disintegrant (5-15% w/w).
                                             It can be used as an adsorbent, antiadherent (20-   90%w/w).
          
4. Talc 
Talc is a purified, hydrated, magnesium silicate.
Synonyms     :     Altalc; E553b; Hydrous magnesium calcium silicate; Hydrous magnesium
silicate;  Luzenac  Pharma;  Magnesium  hydrogen  metasilicate;  Magsil
Osmanthus; Magsil Star; Powdered talc; Purified French chalk; Purtalc;
Soapstone; Steatite; Superiore.
Description      :         Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous,
crystalline powder. It adheres readily to the skin and is soft to the touch
and free from grittiness.
Functional Category:  Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule
lubricant.
Solubility                  :     Practically insoluble in dilute acids and alkalis, organic solvents, and
water.
Stability and Storage   :    Talc is a stable material and may be sterilized by heating at 160°C for
not less than 1 hour. It may also be sterilized by exposure to ethylene
oxide  or  gamma irradiation.  It  should  be  stored  in  a  well-closed
container in a cool, dry place.
Safety                         :       Talc is used mainly in tablet and capsule formulations. It is not
absorbed  systemically  following  oral  ingestion  and  is  therefore
regarded as an essentially nontoxic material. However, intranasal or
intravenous abuse of products containing talc can cause granulomas
in body tissues, particularly the lungs. Contamination of wounds or
body cavities  with  talc  may  also  cause  granulomas;  therefore,  it
should not be used to dust surgical gloves. Inhalation of talc 
                                        causes irritation and may cause severe respiratory distress
                                        in infants.
Incompatibilities : Incompatible with quaternary ammonium compounds.
Uses : Talc can be used in oral solid dosage formulations as a lubricant and
diluent. However, it is  widely used as a dissolution retardant in the
development  of  controlled-release  products.  It  is also  used  as  a
lubricant  in  tablet  formulations; in  a  novel  powder  coating  for
extended-release pellets; and as an adsorbent. In topical preparations,
talc is used as a dusting powder, although it should not be used to dust
surgical gloves.
                                           Talc is additionally used to clarify liquids and is also used in
cosmetics and food products, mainly for its lubricant properties.
5.Magnesium Stearate
Synonyms                     :      Magnesium octadecanoate; Octadecanoic acid, magnesium  salt; 
Stearic acid, magnesium salt.
Functional Category   :    Tablet and capsule lubricant.
Description                :   It is a very fine, light white, precipitated or milled, impalpable powder
of  low  bulk  density,  having  a  faint  odor  of  stearic  acid  and  a
characteristic  taste.  The  powder  is  greasy  to  the  touch  and  readily
adheres to the skin.
Flowability                :      Poorly flowing, cohesive powder.
Melting range           :      117–150°C (commercial samples);
                                           126–130°C (high purity magnesium stearate).
Solubility                   :      Practically insoluble in ethanol, ethanol (95%), ether and       water; 
slightly soluble in warm benzene and warm ethanol (95%).
Stability and Storage :  It  is stable and should be stored in a well-closed container in a cool, 
dry place.
Incompatibilities     :  Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with
strong oxidizing materials.  It  cannot be used in products containing
aspirin, some vitamins, and most alkaloidal salts.
Safety                          :    Nontoxic following oral administration. However, oral consumption of
large quantities may produce a laxative effect or mucosal irritation.
Uses                 :     It is widely used in cosmetics, foods, and pharmaceutical formulations. It is
primarily  used  as  a  lubricant  in  capsule  and  tablet  manufacture  at
concentrations between 0.25% and 5.0% w/w. It is also used in barrier
creams.
6. Colloidal Silicon Dioxide
Nonproprietary Names
• BP: Colloidal anhydrous silica
• PhEur: Silica colloidalis anhydrica
• USPNF: Colloidal silicon dioxide
Synonyms:  Colloidal  silica;  fumed  silica;  light  anhydrous  silicicacid;  silicic  anhydride;
silicondioxide fumed.Wacker HDK. Aerosil; Cab-O-Sil; Cab-O-Sil M-5P;
Chemical Name and CAS Registry Number: Silica 
Structural Formula: SiO2
Uses:  Adsorbent;  anticaking  agent;  emulsion  stabilizer;  glidant;  suspending  agent;  tablet
disintegrant; thermal stabilizer; viscosity-increasing agent.
Table 2.6: Uses of colloidal silicondioxide.
Use
Concentration 
(%)
Aerosols 0.5 - 2.0
Emulsion stabilizer 1.0 – 5.0
Glidant 0.1 - 0.5
Suspending and thickening agent 2.0 – 10.0
Description:  Colloidal  silicon dioxide is  submicroscopic fumed silica with a  particle  size of
about 15 nm. It is a light, loose, bluish-white-colored, odorless, tasteless, nongritty amorphous
powder.
Physical Properties:
Flowability: 35.52% (Carr compressibility index) pH (4% w/v dispersion) 3.5–5.5 
Specific surface area: 200–400 m2/g (Stroehlein apparatus, single point); 50–380 m2/g
(BET method). 
Stability and Storage conditions:  Colloidal silicon dioxide is hygroscopic but adsorbs large
quantities of water without liquefying. The bulk material should be stored in a well-closed in a
cool, dry place.
Incompatibilities: Incompatible with diethylstilbestrol preparations.
7. Stearic acid
Nonproprietary Names
BP: Stearic acid
JP: Stearic acid
PhEur: Acidum stearicum
USPNF: Stearic acid
Synonyms
Cetylacetic acid; Crodacid; E570; Edenor; Emersol; Hystrene; Industrene; Kortacid 1895; Pearl
Steric; Pristerene; stereophonic acid; Tegostearic.
Chemical Name and CAS Registry Number
Octadecanoic acid 
Empirical Formula and Molecular Weight
C18H36O2 284.47 (for pure material)
The USPNF 23 describe stearic acid as a mixture of stearic acid (C18H36O2) and palmitic acid
(C16H32O2). In the USPNF 23, the content of stearic acid is not less than 40.0% and the sum of
the two acids is not less than 90.0%. The USPNF 23 also contains a monograph for purified
stearic acid. The PhEur 2005 contains a single monograph for stearic acid but defines stearic acid
50,  stearic  acid  70,  and  stearic  acid  95  as  containing  specific  amounts  of  stearic  acid
(C18H36O2); 
Functional Category Emulsifying agent; solubilizing agent; tablet and capsule lubricant.
Applications in Pharmaceutical Formulation or Technology
Stearic acid is widely used in oral and topical pharmaceutical formulations. It is mainly used in
oral formulations as a tablet and capsule lubricant, although it may also be used as a binder or in
combination with shellac as a tablet coating. It has also been suggested that stearic acid may be
used  as  a  sustained-release  drug  carrier.  In  topical  formulations,  stearic  acid  is  used  as  an
emulsifying and solubilizing agent. When partially neutralized with alkalis or triethanolamine,
stearic acid is used in the preparation of creams. The partially neutralized stearic acid forms
acreamy base when mixed with 5–15 times its own weight ofaqueous liquid; the appearance and
plasticity of the cream being determined by the proportion of alkali used. Stearic acid is used as
the hardening agent in glycerin suppositories. Stearic acid is also widely used in cosmetics and
food products.
Description
Stearic acid is a hard, white or faintly yellow-colored, somewhat glossy, crystalline solid or a
white or yellowish white powder. It has a slight odor and taste suggesting tallow. 
Stability and Storage Conditions 
Stearic acid is a stable material; an antioxidant may also be added to it. The bulk material should
be stored in a well-closed container in a cool, dry place. 
Incompatibilities
Stearic acid is incompatible with most metal hydroxides and may be incompatible with oxidizing
agents. Insoluble stearates are formed with many metals; ointment bases made with stearic acid
may show evidence of drying out or lumpiness due to such a reaction when compounded with
zinc or calcium salts. A number of differential scanning calorimetry studies have investigated the
compatibility  of  stearic  acid  with  drugs.  Although  such  laboratory  studies  have  suggested
incompatibilities,  e.g.  with  naproxen,  they  may not  necessarily  be  applicable  to  formulated
products. Stearic acid has been reported to cause pitting in the film coating of tablets coated
using an aqueous film-coating technique; the pitting was found to be a function of the melting
point of the stearic acid.
Safety
Stearic acid is widely used in oral and topical pharmaceutical formulations; it is also used in
cosmetics and food products. Stearic acid is generally regarded as a nontoxic and nonirritant
material. However, consumption of excessive amounts may be harmful.
LD50 (mouse, IV): 23 mg/kg
LD50 (rat, IV): 21.5 mg/kg
8. Polyethylene Glycol
Nonproprietary Names
BP: Macrogols
JP: Macrogol 400
Macrogol 1500
Macrogol 4000
Macrogol 6000
Macrogol 20000
PhEur: Macrogola
USPNF: Polyethylene glycol
Synonyms
Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; PEG; Pluriol E; polyoxyethylene glycol.
Chemical Name and CAS Registry Number
a-Hydro-o-hydroxypoly(oxy-1,2-ethanediyl) 
Empirical Formula and Molecular Weight
HOCH2(CH2OCH2)mCH2OH where m represents the average number of oxyethylene groups.
Alternatively, the general formula
Structural Formula
Functional Category
Ointment base; plasticizer; solvent; suppository base; tablet and capsule lubricant.
Applications in Pharmaceutical Formulation or Technology
Polyethylene  glycols  (PEGs)  are  widely  used  in  a  variety  of  pharmaceutical  formulations
including  parenteral,  topical,  ophthalmic,  oral,  and  rectal  preparations.  It  has  been  used
experimentally  in  biodegradable  polymeric  matrices  used  in  controlled-release  systems.
Polyethylene glycols are stable, hydrophilic substances that are essentially nonirritant to the skin.
They do not readily penetrate the skin, although the polyethylene glycols are water-soluble and
are easily removed from the skin by washing,  making them useful  as ointment  bases.  Solid
grades  are  generally  employed  in  topical  ointments,  with  the  consistency of  the  base  being
adjusted  by  the  addition  of  liquid  grades  of  polyethylene  glycol.  Mixtures  of  polyethylene
glycols can be used as suppository bases, for which they have many advantages over fats. For
example,  the melting point  of  the suppository can be made higher  to withstand exposure to
warmer climates; release of the drug is not dependent upon melting point; the physical stability
on  storage  is  better;  and  suppositories  are  readily  miscible  with  rectal  fluids.  Polyethylene
glycols have the following disadvantages: they are chemically more reactive than fats; greater
care is needed in processing to avoid inelegant contraction holes in the suppositories; the rate of
release  of  water-soluble  medications  decreases  with  the  increasing  molecular  weight  of  the
polyethylene glycol; and polyethylene glycols tend to be more irritating to mucous membranes
than fats. Aqueous polyethylene glycol solutions can be used either as suspending agents or to
adjust the viscosity and consistency of other suspending vehicles. When used in conjunction with
other emulsifiers, polyethylene glycols can act as emulsion stabilizers.
Liquid polyethylene glycols are used as water-miscible solvents for the contents of soft gelatin
capsules. However, they may cause hardening of the capsule shell by preferential absorption of
moisture from gelatin in the shell. In concentrations up to approximately 30% v/v, PEG 300 and
PEG  400  have  been  used  as  the  vehicle  for  parenteral  dosage  forms.  In  solid-dosage
formulations,  higher-molecular-weight  polyethylene  glycols  can  enhance  the  effectiveness  of
tablet binders and impart plasticity to granules. However, they have only limited binding action
when used alone, and can prolong disintegration if present in concentrations greater than 5%
w/w. When used for thermoplastic granulations, a mixture of the powdered constituents with 10–
15% w/w PEG 6000 is heated to 70–75°C. The mass becomes paste like and forms granules if
stirred  while  cooling.  This  technique  is  useful  for  the  preparation  of  dosage  forms  such  as
lozenges when prolonged disintegration is required. Polyethylene glycols can also be used to
enhance the aqueous solubility or dissolution characteristics of poorly soluble compounds by
making solid dispersions with an appropriate polyethylene glycol. Animal studies have also been
performed using polyethylene glycols as solvents for steroids in osmotic pumps. In film coatings,
solid grades of polyethylene glycol can be used alone for the film-coating of tablets or can be
useful as hydrophilic polishing materials. Solid grades are also widely used as plasticizers in
conjunction with film-forming polymers.  The presence of polyethylene glycols in film coats,
especially of liquid grades, tends to increase their water permeability and may reduce protection
against  low  pH  in  enteric-coating  films.  Polyethylene  glycols  are  useful  as  plasticizers  in
microencapsulated products to avoid rupture of the coating film when the microcapsules  are
compressed into tablets.
Polyethylene glycol grades with molecular weights of 6000 and above can be used as lubricants,
particularly for soluble tablets. The lubricant action is not as good as that of magnesium stearate,
and  stickiness  may  develop  if  the  material  becomes  too  warm  during  compression.  An
antiadherent effect is also exerted, again subject to the avoidance of overheating. Polyethylene
glycols have been used in the preparation of urethane hydrogels, which are used as controlled-
release agents.  It  has also been used in insulin-loaded microparticles for the oral  delivery of
insulin, it has been used in inhalation preparations to improve aerosolization, polyethylene glycol
nano particles have been used to improve the oral bioavailability of cyclosporine, it has been
used in self assembled polymeric nano particles as a drug carrier, and copolymer networks of
polyethylene  glycol  grafted  with  poly(methacrylic  acid)  have  been  used  as  bioadhesive
controlled drug delivery formulations.
9. Hydrogenated Vegetable Oil
Non proprietary names:   
          BP: Hydrogenated vegetable oil
            JP: Hydrogenated oil
            USPNF: Hydrogenated vegetable oil
Synonyms:
             Hydrogenated cottonseed oil: Akofine; Lubritab; Sterotex.
             Hydrogenated palm oil: Softisan 154.
             Hydrogenated soybean oil: Lipovol HS-K; Sterotex HM
Chemical name and CAS registry no:
            Hydrogenated vegetable oil [68334-00-9]
Empirical formulae:
                 R1COOCH2—CH(OOCR2)—CH2OOCR3
                 where R1, R2, and R3 are mainly C15 and C17.
Functional category:
               Tablet and capsule lubricant; tablet binder
Description: 
               Hydrogenated vegetable oil is a mixture of triglycerides of fattyacids. The two 
types that are defined in the USPNF 23 are characterized by their physical properties; 
Hydrogenated vegetable oil type I occurs in various forms,e.g. fine powder, flakes, or 
pellets. The color of the materialdepends on the manufacturing process and the form. In 
general,the material is white to yellowish-white with the powder gradesappearing more 
white-colored than the coarser grades.
Typical properties:
                   Density (tapped): 0.57 g/cm3 
                   Melting point: 61–668C 
                   Particle size distribution: 85% < 177 mm, 25% < 74 mm in size
                   Average particle size is 104 mm.
                   Solubility: soluble in chloroform, petroleum spirit, and hot propan-2-ol; 
practically  insoluble in water.
Stability and Storage Conditions:
Hydrogenated vegetable oil type I is a stable material; typically it is assigned a 2-year 
shelf-life. The bulk material should be stored in a well-closed container in a cool, dry 
place.
Incompatibilities: 
                     Incompatible with strong oxidizing agents.
Safety:
                      Hydrogenated vegetable oil type I is used in food products and oral 
pharmaceutical formulations and is generally regarded as a nontoxic and nonirritant 
excipient.
Applications: 
  Hydrogenated vegetable oil type 1 is used as a lubricant in tablet and capsule     
formulations. It is used at concentrations of 1–6% w/w, usually in combination with talc. 
 It may also be used as an auxiliary binder in tablet formulations.
 Hydrogenated vegetable oil type I is additionally used as the matrix-forming 
material in lipophilic-based controlled-release formulations; 
 It may also be used as a coating aid in controlled-release formulations.
 Hydrogenated vegetable oil type I is used as a viscosity modifier in the 
preparation of oil-based liquid and semisolid formulations
 In the preparation of suppositories, to reduce the sedimentation of suspended 
components and to improve the solidification process
 In the formulation of liquid and semisolid fills for hard gelatin capsules. 
Table 5 : Instruments Used
The total dose of Eplerenone for biphasic delivery was calculated with available pharmacokinetic
data.  (  Martin  J.,  2001)As per  the zero order  release principle,  the rate  of  delivery must  be
independent of the amount of drug remaining in the dosage form and constant over time. The
release  from the  dosage  form should  follow zero-order  kinetics,  as  shown  by the  equation.
(Robinson and Eriksen, 1966)
K0r = Rate in= Rate out = ke×Cd×Vd. Eq. (1)
Where K0r  is the zero-order rate constant for drug release (amount per time), ke is the first order
rate constant of overall drug elimination (per hour), Cd is the desired drug level in the body
          Instrument Name            Manufacturer              Model
Weighing balance Sartorius CP225D
Analytical  balance Essae DS-852 DS-852
Tray dryer  Millennium equipments Pvt Ltd METD-6G
Tablet compression 
machine
Rimek (Karnavathi) D tooling
Friablitor Electrolab EF-2(USP)
Hardness tester Electrolab EH01
Dissolution test system Electrolab TDT-14L
Mechanical stirrer Vision labs NA
Coating pan Bectochem GMP4938
HPLC Schimadzu LC2010CHT
(amount per volume), and Vd is the volume in which the drug is distributed. The elimination
half-life of Eplerenone is 4 h (ke= 0.693/4=0.173h-1)
The loading dose is required to give initial rapid burst of dose so as to attain therapeutic range
immediately after dosing 
Loading dose (DL) = Css avg×Vd / F = (0.2495×66.5) / 0.69 = 24mg Eq. (2)
Where DL = Loading Dose, 
Css avg = Average Steady State Concentration (0.2495 mg/ml),
Vd = Apparent Volume of Distribution (66.5 l),
F = Fraction of Dose Absorbed (0.69). 
The maintenance dose was (DM) = K0 r× H, Eq. (3)
H = Total desired time for sustained action in hours, 
Drug availability rate (Rate of drug input) K0 r= Ke× DL Eq. (4) 
Ke is the overall elimination rate constant (per hour), 
K0 r= 0.1732 ×12 = 2.0784 mg / h. 
Thus K0 r  (Rate of drug input) is  4.158 mg /  h,  which should also have been equal to the
elimination constant  so as to maintain the steady state condition.  For a  system in which the
maintenance dose releases drug by a zero order p7rocess for a specified time, the total dose is as
follows: 
Total dose = DT = DL*+DM, Eq. (5) 
DL *is corrected loading dose 
DM = K0 r×H= 2.0784 ×12 = 24.94 mg
If the maintenance dose begins the release of the drug at the time of dosing, it will add to that
which  is  provided  by the  initial  dose,  thus  increasing  the  initial  drug  level.  In  this  case,  a
correction factor is needed (K0 r× TP) to account for the added drug from the maintenance dose.
This correction factor is the amount of drug provided during the period from t=0 to the time of
the peak drug level, TP. 
If DL is 24mg, K0 r is 4.158 mg/h, and TP is 1.5h, then the corrected loading dose 
(DL*)= DL- (K0 r×TP) = 2.0784 ×1.5= 20.88 Thus, 
The total dose required (DT) =DL*+DM=20.88 +49.89= 70.77 mg 
The total dose of Eplerenone rounded off to 70 mg (which is equivalent to 74 mg of
Eplerenone with 24 mg loading dose and 49.89 mg maintenance dose)( Madhusudan Rao Y. et
al., 2011)
Construction of Standard Graph of Eplerenone 
Accurately  weighed  amount  of  120  mg  Eplerenone  was  transferred  into  a  100ml
volumetric flask. 20 mL of 0.1N hydrochloric acid (HCl) was added to dissolve the drug and
volume was made up to 100 mL with the same HCl. The resulted solution had the concentration
of 1mg/ml which was labeled as ‘stock’. From this stock solution 10ml was taken and diluted to
100 mL with 0.1N HCl which has given the solution having the concentration of 120 mcg/mL.
Necessary dilutions were made by using this second solution to give the different concentrations
of Eplerenone (80 to 120mcg/mL) solutions.
                      
             Similarly, standard graph was plotted with 6.8 pH phosphate buffer.
PREFORMULATION STUDIES:
Preformulation studies are primarily done to investigate the physicochemical properties of drug
and to establish its compatibility with other excipients.
Drug-Excipients Compatibility studies:
Eplerenone was mixed with all excipients, used in the formulation in different ratios and
subjected to Physical observation.
Drug-Excipient  Compatibility  study  (Physical  Observation):  Eplerenone  was  mixed  with
different proportions with all excipients which were used in the formulation, in different ratios
and kept at 40oC/75%RH conditions for one month. The physical properties (Color change) were
monitored regularly. The change in color of any mixture was considered as incompatibility and
the excipient blend was discarded from stud
Table 6:
S.No Drug excipients blend Ratio Condition: 40°C ± 2°C / 75% ± 5%
Initial 1
week
2
weeks
4
weeks
1 Eplerenone + sucrose
1:1
White  to  Off  white
crystalline powder
2 Eplerenone+hypromellose 1:1 White to Off white powder
3 Eplerenone  +  Aqua  coat
ARC 
1:1
White to Off white powder
4 Eplerenone+Ethyl
cellulose
1:1
White to Off white powder
5 Eplerenone + Surelease 1:1 White to Off white powder
6 Eplerenone + MCC 1:1 White to Off white powder
7 Eplerenone + Mg.stearate. 1:1 White to Off white powder
8 Eplerenone + Lubritab 1:1 White to Off white powder
9 Eplerenone + Talc 1:1 White to Off white powder
10 Eplerenone + Stearic acid 1:1 White to Off white powder
11 Eplerenone + PEG 6000 1:1 White to Off white powder
12 Eplerenone+  sucrose+
hypromellose+  Aqua  coat
ARC+  Ethyl  cellulose  +
Surelease+  MCC+
Mg.stearate+  Lubritab  +
Talc+  Stearic  acid+  PEG
6000
1:1:1:1
:1:1:1:
1:1:1:1
:1
White  to  Off  white
crystalline powder
13 Sucrose+  hypromellose+
Aqua  coat  ARC+  Ethyl
cellulose  +  Surelease+
1:1:1:1
:1:1:1:
1:1:1:1
White  to  Off  white
crystalline powder
MCC+  Mg.stearate+
Lubritab  +  Talc+  Stearic
acid+ PEG 6000
Preparation of Eplerenone sustained release Tablets (MUPS):
Table 7: Composition of Pellet formulations: 
Ingredients       
Drug loading Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 Trial 6
Eplerenone 50 50 50 50 50 50
Sugar spheres (#35 - #40) 29 29 28 29 29 29
Aerosil 0.7 0.7 0.7 0.7 0.7 0.7
Sucrose 0 4 4.8 7.05 10.3 7.7
Binder solution       
Sugar 10 5 2 2 2 2
HPMC E5 3 1.5 0.6 0.6 0.6 0.6
Purified water Q.S Q.S Q.S Q.S Q.S Q.S
Coating       
Ethyl cellulose No Coating
has been
done bcz of
the pellets
were not
good
enough
(physical
properties)
No Coating
has been
done bcz of
the pellets
were not
good
enough
(physical
properties)
10 7.5 5 0
Surelease 0 0 0 10
Stearic acid (20% of EC) 2 1.5 1 0
PEG 6000 (10% of EC) 1 0.75 0.5 0
Talc 0.9 0.9 0.9 0
IPA Nil Nil Nil Nil
Purified water Q.S Q.S Q.S Q.S
Table 8: Composition of Pellet formulations:
Drug loading Trial 7 Trial 8 Trial 9 Trial 10 Trial 11
Eplerenone 50 50 50 50 50
Sugar spheres (#35 - #40) 29 29 29 29 29
Aerosil 0.7 0.7 0.7 0.7 0.7
Sucrose 10.2 12.7 3.8 7.05 10.3
Binder solution    
Sugar 2 2 2 2 2
HPMC E5 0.6 0.6 0.6 0.6 0.6
Purified water Q.S Q.S Q.S Q.S Q.S
Coating      
Surelease 7.5 5 0 0 0
Aqua coat ARC 0 0 10 7.5 5
Stearic acid(20% of EC) 0 0 2 1.5 1
PEG 6000(10% of EC) 0 0 1 0.75 0.5
Talc 0 0 0.9 0.9 0.9
IPA Nil Nil Q.S Q.S Q.S
Purified water Q.S Q.S Q.S Q.S Q.S
Table 9: Composition of Tablet formulations
Ingredients F 1 F 2 F 3 F 4
Compression
Eplerenone Pellets 50% w/w 140.00 140.00 140.00 140.00
MCC pH 102 244.00 234.00 229.00 224.00
Aerosil 2.00 2.00 2.00 2.00
Lubritab 0.00 10.00 15.00 20.00
Magnesium stearate 2.00 2.00 2.00 2.00
Film Coating     
Opadry white 12.00 12.00 12.00 12.00
Purified water Q.S Q.S Q.S Q.S
The selected manufacturing process for the preparation of Eplerenone Sustained release tablets
given below,
DRUG LAYERING
1. Sifting:
Sift Eplerenone & sucrose through #100 in Vibro Sifter and collect in pre-labeled double
lined polythene bag in HDPE Containers
2. Blending:
Transfer the sifted materials to Conta blender and blend for about 15 minutes at 12 RPM.
After  completion  of  the  blending  unload  the  material  into  pre-labeled  double  lined
polythene bag HDPE Containers
3. Binder solution preparation: 
Take the Purified water in SS container. Add Hypromellose, Sucrose (Syrup grade) in
purified water under continuous stirring till the clear solution is obtained Filter the clear
solution through #200 nylon cloth into a cleaned SS container.
4. Pellatization: 
Load the Sugar spheres (#35-#40) in to coating pan and start the coating pan and allow
the spheres to rotate. Adjust the spray gun atomization air pressure to 1.0-2.0 kg/sq cm.
Start the peristaltic pump and adjust to 5 - 15 RPM. Start spraying the syrup solution by
adjusting the gun distance (30-40 cm). Continue spraying till the spheres become wet.
Add drug blend in small quantities to the wet pellets in the coating pan until the spheres
are free flowing. Adjust the Peristaltic pump 15- 30 RPM and continue the spraying of
syrup  solution  and  powder  addition  till  the  complete  drug  blend  is  exhausted  After
completion of the process unload the wet drug pellets into trays in equal quantities and
keep for drying.
5. Drying:
Load the wet drug coated pellets into Tray drier trays and load the trays into Tray Drier.
Set the inlet temperature at 45±3°C and maintain the bed temperature between 42°- 48°C.
NOTE: i) Record the drying parameters every one hour.
 ii)   Rake the pellets at every 1 hour.
 iii) Drug pellets drying up to Moisture Content should be below 2.0%.  
6. Sifting:
Check the integrity of the sieve/screen before and after sifting. Record the observations
and action taken in case of damage if any. Sift the dried pellets through #25 and collect
30# retains and passing separately into double lined polythene bag HDPE containers. Sift
#25 passing pellets  through #30and collect  retains and passing separately into double
lined  polythene  bag  HDPE  containers.  The  sifted  pellets  are  colleted  into  HDPE
containers lined with double polythene bags. Wear latex hand gloves during operations
COATING PROCESS:
1. Preparation of coating solution:
a) Ethyl Cellulose solution: Pass the Isopropyl Alcohol through #200 Nylon cloths into
SS container.  Dissolve  the  in  half  quantity  of  Isopropyl  Alcohol  with  continuous
stirring.  Dissolve  the  PEG  6000  in  purified  water  with  continuous  stirring  in  a
separate  container.  Mix  the  above  prepared  Magnesium  stearate  and  PEG  6000
solution to Ethyl Cellulose. Solution with continues stirring for 15 minuties. After
stirring, filter the solution through #200 Nylon cloths into separate SS containers.
b) Surelease  solution:  Add  Surelease  to  purified  water  with  continuous  stirring  to
prepare the dispersion of 15% solid content.
c) Aquacoat  ARC: Add Aquacoat  ARC to purified  water  with  continuous stirring to
prepare the dispersion of 15% solid content.
2. Coating process:
Load the Drug coated pellets into the product bowl and carry out the operation as Per
Standard Operating Procedures. Set the inlet temperature to 45°-60°C & maintain the bed
temperature between 38o-44oc for Ethyl cellulose coating and 40o-50oc for Surelease and
Aquacoat ARC coating by adjusting the Inlet set temperature. Coat the drug pellets by
bottom spray Wurster at peristaltic pump rpm of 2 to 20 and atomizing air pressure of 0.5
- 2.0 Kg/cm2 till the coating solution is completed. After completion of solution, dry the
pellets in FBC for about 15 minutes at given bed temperature & Atomization air pressure
2.0kgs/cm2.  After  drying,  unload  the  pellets  into  pre-labeled  HDPE  containers  with
double lined polythene bags. If there is any breakage or lumps were observed during the
coating, sift the pellets through suitable sieve to remove them.  
3. Sifting:
Sift the coated pellets through # 25 and collect # 30 retains and passing separately into
double lined Polythene bag HDPE containers. Collect the filled capsules in to IPC lined
with virgin double polythene bags. Store the pellets below 25 º C.
COMPRESSION 
Sift all the excipients through the sieve no #40 add the pellets to this dry blend and blend well in
the blender for 5 min. 
Compress the lubricated blend with the following specifications
Compression specifications:
Table 10:
Description White colored round shaped tablets
Tooling 12 mm round shape
Hardness 60-75N
Thickness 3.40-4.20mm
Friability NMT 1% w/w
Uniformity of Weight ± 5% of average weight
FILM COATING 
Prepare the film coating solution with opadry white. Add slowly opadry to the water stir well
until the uniform dispersion formed. Coat the tablets until the coating weight buildup is reached
 
Evaluation of Pre-compression Blend
The quality of tablet, once formulated by rule, is generally dictated by the quality of
physicochemical  properties  of  blends.  There  are  many  formulations  and  process  variables
involved in mixing and all these can affect the characteristics of blends produced. 
The various characteristics of blends tested are as given below: 
Angle of repose 
The frictional force in a loose powder can be measured by the angle of repose (θ). It is
defined as, the maximum angle possible between the surface of the pile of the powder and the
horizontal plane. If more powder is added to the pile, it slides down the sides of the pile until the
mutual  friction  of  the  particles  producing  a  surface  angle  θ,  is  in  equilibrium  with  the
gravitational force. 
The fixed funnel method was employed to measure the angle of repose. A funnel was
secured with its tip at a given height (h), above a graph paper that is placed on a flat horizontal
surface. The blend was carefully pored through the funnel until the apex of the conical pile just
touches the tip of the funnel. The radius (r) of the base of the conical pile was measured. The
angle of repose (θ) was calculated using the following formula:
                             Tan θ = h/r 
Where;          θ = Angle of repose 
                     h = Height of the cone 
                     r = Radius of the cone base 
Angle of repose less than 300 shows the free flowing of the material. 
Bulk density
Density is defined as weight per unit volume. Bulk density, ρb, is defined as the mass of
the powder divided by the bulk volume and is  expressed as  gm/cm3.  The bulk density of  a
powder  primarily  depends  on  particle  size  distribution,  particle  shape  and  the  tendency  of
particles to adhere together. 
About  30  g  powder  blend  was  introduced  into  a  dry  100  mL  cylinder,  without
compacting. The powder was carefully leveled without compacting and the unsettled apparent
volume, Vo, was read. The bulk density was calculated using the formula:
                                            ρb = M / Vo
Where                        ρb = Apparent Bulk Density  
                                  M = weight of sample 
                                  V = apparent volume of powder  
Tapped density
After carrying out the procedure as given in the measurement of bulk density the cylinder
containing the sample was tapped using a suitable mechanical tapped density tester that provided
a fixed drop of 14 ± 2 mm at a nominal rate of 300 drops per minute. The cylinder was tapped
500  times  initially  followed  by  an  additional  tap  of  750  times  until  difference  between
succeeding measurement was less than 2 % and then tapped volume, Vf was measured, to the
nearest graduated unit. The tapped density was calculated, in gm per mL, using the formula: 
                                     ρtap = M / Vf
Where                        ρtap  = Tapped Density  
                                  M = Weight of sample & Vf = Tapped volume of powder  
Measures of powder compressibility 
The Compressibility Index (Carr’s Index) is a measure of the propensity of a powder to
be  compressed.  It  is  determined  from  the  bulk  and  tapped  densities.  In  theory,  the  less
compressible a material the more flowable it is. As such, it is measure of relative importance of
inter  particulate  interactions.  In  a  free-flowing  powder,  such  interactions  are  generally  less
significant,  and  the  bulk  and  tapped  densities  will  be  closer  in  value.  For  poorer  flowing
materials, there are frequently greater inter particle interactions, and a greater difference between
the  bulk  and  tapped  densities  will  be  observed.  These  differences  are  reflected  in  the
Compressibility Index which is calculated using the following formula:
Car r
'
sIndex=[ ( ρtap−ρb)ρtap ]100
Where           ρb = Bulk Density  
                  ρtap  = Tapped Density 
 
                         Table 11: Carr’s Index Values
S. No. Carr’s Index Properties
1 5-12 Free flowing
2 13-16 Good
3 18-21 Fair
4 23-35 Poor
5 33-38 Very poor
6 >40 Extremely poor
Evaluation of pellets
During the drug layering process 
i) Size of the pellets
Sift the pellets through specified sieve #25-#30 not more than 10% the pellets retain on the sieve
no#25 and not more than 10 % pellets pass through the sieve no #30
ii) Assay
The drug content of the pellets was determined according to in-house standards and it meets the
requirements if the amount of the active ingredient in each of the 100mg contain 50mg and lies
within the range of 95% to 105% of the standard amount.
            Pellets were weighed and taken into a mortar and crushed into fine powder. An accurately
weighed portion of the powder equivalent to about 100 mg of Eplerenone was transferred to a
100 mL volumetric flask containing 70 mL of 0.1N HCl. It was shaken by mechanical means for
1h.Then it was filtered through a Whatman filter paper (No. 1) and diluted to 100 mL with 0.1N
HCl.  From  this  resulted  solution  1  mL was  taken,  diluted  to  50  mL with  0.1N  HCl  and
absorbance was measured at 240 nm.
After coating 
i) Size of the pellets
Sift the pellets through specified sieve #25-#30 not more than 10% the pellets retain on the sieve
no#25 and not more than 10 % pellets pass through the sieve no #30  
ii) Assay
The drug content of the pellets was determined according to in-house standards and it meets the
requirements if the amount of the active ingredient in each of the 100mg pellets contains 50mg
and lies within the range of 95% to 105% of the standard amount.
            Pellets were weighed and taken into a mortar and crushed into fine powder. An accurately
weighed portion of the powder equivalent to about 100 mg of Eplerenone was transferred to a
100 mL volumetric flask containing 70 mL of 0.1N HCl. It was shaken by mechanical means for
1h.Then it was filtered through a Whatman filter paper (No. 1) and diluted to 100 mL with 0.1N
HCl.  From  this  resulted  solution  1  mL was  taken,  diluted  to  50  mL with  0.1N  HCl  and
absorbance was measured at 240 nm.
iii) Dissolution
Drug release was assessed by dissolution test under the following conditions: n = 3,  USP type I
dissolution apparatus at 50 rpm in 900 mL of  0.1N HCl for first 2 hours and the phosphate
buffer pH 6.8 from 3 to 12 hours, maintained at 37°C ± 0.5°C.  An aliquot (5mL) was withdrawn
at specific time intervals and replaced with the same volume of prewarmed (37°C ± 0.5°C) fresh
dissolution medium. The samples withdrawn were filtered through Whatman filter paper (No.1)
and drug content in each sample was analyzed by HPLC with UV-visible detector at 240 nm.    
6.6. Evaluation of Tablets (MUPS)
i) Thickness
               Twenty tablets from the representative sample were randomly taken and individual
tablet thickness was measured by using digital vernier caliper. Average thickness and standard
deviation values were calculated.
ii) Hardness
            Tablet hardness was measured by using Monsanto hardness tester. From each batch six
tablets were measured for the hardness and average of six values was noted along with standard
deviations.
iii) Friability Test
          From each batch, ten tablets were accurately weighed and placed in the friability test
apparatus (Roche friabilator). Apparatus was operated at 25 rpm for 4 minutes and tablets were
observed while rotating. The tablets were then taken after 100 rotations, dedusted and reweighed.
The friability was calculated as the percentage weight loss.
Note: No tablet should stick to the walls of the apparatus. If so, brush the walls with talcum
powder. There should be no capping also.
  % friability was calculated as follows
              
                                 % Friability = (W1 – W2) x 100/W1
                             where W1 = Initial weight of the 20 tablets.
                                       W2 = Final weight of the 20 tablets after testing.
Friability values below 0.8% are generally acceptable.
iv) Weight Variation Test 
           To study weight variation individual weights (WI) of 20 tablets from each formulation
were noted using electronic balance. Their average weight (WA) was calculated. Percent weight
variation was calculated as follows. Average weights of the tablets along with standard deviation
values were calculated.
                            % weight variation = (WA–WI) x 100/ WA
           As the total tablet weight was 120 mg, according to IP 1996, out of twenty tablets ±7.5 %
variation can be allowed for not more than two tablets.
           According to USP 2004, ±10% weight variation can be allowed for not more than two
tablets out of twenty tablets.
v) Drug Content (Assay)
       The drug content of the matrix tablets was determined according to in-house standards and it
meets the requirements if the amount of the active ingredient in each of the 10 tested tablets lies
within the range of 95% to 105% of the standard amount.
            Ten tablets were weighed and taken into a mortar and crushed into fine powder. An
accurately  weighed  portion  of  the  powder  equivalent  to  about  100  mg  of  Eplerenone  was
transferred to a  100 mL volumetric  flask containing 70 mL of  0.1N HCl.  It  was shaken by
mechanical means for 1h.Then it was filtered through a Whatman filter paper (No. 1) and diluted
to 100 mL with 0.1N HCl. From this resulted solution 1 mL was taken, diluted to 50 mL with
0.1N HCl and absorbance was measured at 240 nm.
vi) Content uniformity (Assay)
Select not fewer than 30 units, and proceed as follows for the dosage form designated
Assay 10 units individually using assay method has said previously. Calculate the acceptance
criteria value by the formula
|M − X|+ks
X= Mean of individual contents (x1,x2,..x n), expressed as a percentage of the label claim
n= Sample size (number of units in asample)
k= Acceptability constant, If n = 10, then k =2.4
k= Acceptability constant, If n = 10, then k =2.0
M value calculation is given in the below table
Table 12
vii) In -Vitro Drug Release Characteristics
           Drug release was assessed by dissolution test under the following conditions: n = 3,  USP
type I dissolution apparatus at 50 rpm in 900 mL of  0.1N HCl for first 2 hours and the phosphate
buffer pH 6.8 from 3 to 12 hours, maintained at 37°C ± 0.5°C.  An aliquot (5mL) was withdrawn
at specific time intervals and replaced with the same volume of prewarmed (37°C ± 0.5°C) fresh
dissolution medium. The samples withdrawn were filtered through Whatman filter paper (No.1)
and drug content in each sample was analyzed by HPLC with UV-visible detector at 240 nm.    
viii) Kinetic Analysis of Dissolution Data
             To analyze the in vitro release data various kinetic models were used to describe the
release kinetics. The zero order rate Eq. (1) describes the systems where the drug release rate is
independent of its concentration (Hadjiioannou et al., 1993). The first order Eq. (2) describes the
release  from system where  release  rate  is  concentration  dependent  (Bourne,  2002).  Higuchi
(1963) described the release of drugs from insoluble matrix as a square root of time dependent
process based on Fickian diffusion Eq. (3). The Hixson-Crowell cube root law Eq. (4) describes
the release from systems where there is a change in surface area and diameter of particles or
tablets (Hixson and Crowell, 1931).
                  C = K0 t                                                                                                  (1)                 
where, K0 is zero-order rate constant expressed in units of concentration/time and t is the time.
 
                   LogC = LogC0  - K1 t / 2.303                                                                  (2)
where, C0 is the initial concentration of drug and K1 is first order constant.
 
                 Q = KHt1/2                                                                                                         (3)
where, KH is the constant reflecting the design variables of the system.
          
                  Q01/3 – Qt1/3 = KHC t                                                                                   (4)
where, Qt  is the amount of drug remained in time t, Q0 is the initial amount of the drug in tablet
and KHC is the rate constant for Hixson-Crowell rate equation.
 The following plots were made using the in-vitro drug release data
Cumulative % drug release vs. time (Zero order kinetic model);
 Log cumulative of % drug remaining vs. time (First order kinetic model);
Cumulative % drug release vs. square root of time (Higuchi model);
And cube root of initial concentration minus the cube root of percentage of drug remaining in the
matrix vs. time (Hixson-Crowell cube root law).
viii) Mechanism of drug release
             Korsmeyer et al (1983) derived a simple relationship which described drug release from
a polymeric system Eq. (5). To find out the mechanism of drug release, first 60% drug release
data was fitted in Korsmeyer–Peppas model.
                                      Mt / M∞ = Ktn                                                                    (5)             
where Mt / M∞ is fraction of drug released at time t, K is the release  rate constant incorporating
structural and geometric characteristics of the tablet, and n is the release exponent. The n value is
used to characterize different release mechanisms. 
            A plot of log cumulative % drug release vs. log time was made. Slope of the line was n.
The n value is used to characterize different release mechanisms as given in Table16, for the
cylindrical shaped matrices. Case-II generally refers to the erosion of the polymeric chain and
anomalous  transport  (Non-Fickian)  refers  to  a  combination  of  both  diffusion  and  erosion
controlled-drug release (Peppas, 1985).
Table 13:   Diffusion Exponent and Solute Release Mechanism for Cylindrical Shape 
ix) In vitro drug release studies 
Dissolution 
Apparatus :  Dissolution test as per USP, apparatus І
Dissolution medium : pH 1.2 buffer for 2 hours and 6.8 phosphate buffer for 10 hrs
Volume (ml)  :         900 mL
Rpm              :        50
Temperature  :       37.5+0.5ºC
Time               :        2, 4, 6, 9 and 12hrs 
Wavelength (nm)  :       240nm
Procedure: Weighed the pellets equivalent to 100 mg of Eplerenone transfer individually to six
dissolution bowls having 900ml pH 1.2 buffer equilibrated to 37.0±0.5°C taking care to exclude
air bubbles from the surface of the pellets and start apparatus for 2 hrs. then transfer the the
pellets after 2 hrs in to 900 mL of 6.8 Phosphate buffer carefully using a filter, follow the same
procedure and same parameters continued for this media also. 
Samples will be taken for specified time points
Diffusion exponent (n) Overall solute diffusion mechanism
0.45 Fickian diffusion
0.45 < n < 0.89 Anomalous (non-Fickian) diffusion
0.89 Case-II transport
n > 0.89 Super case-II transport
HPLC Conditions:
 A. Chromatographic conditions 
Samples were assayed for Eplerenone using a sensitive HPLC method with UV-detection.
Chromatography was performed on A Stainless steel column (inertsil ODS 3 V 250mm, 4.6mm,
5µ  ID) 250mm long, 4.6mm internal diameter filled with octadecylsilance chemically bonded
with silica gel particles of 5 µm diameter. The mobile-phase consisted of acetonitrile and pH 2.0
buffer (30:70, v/v), The flow rate was 1.5ml/ min. Ultraviolet detection was set at wavelength of
240nm and the column temperature was kept at 40oC.( Madhusudan Rao Y. et al., 2011)
Preparation of pH 6.8 phosphate buffer :  Accurately measured 50 mL of 0.2 M potassium
dihydrogen orthophosphate was transferred to a 200mL volumetric flask and 22.4 mL of 0.2 M
sodium hydroxide was added to it. Volume was made up to 200 mL with distilled water, mixed
and pH was adjusted to 6.8 with 0.2 M sodium hydroxide or 0.2 M othophosphoric acid. 
Preparation of 0.2 M potassium dihydrogen phosphate solution: Accurately weighed 27.218
g of monobasic potassium dihydrogen phosphate was dissolved in 1000 mL of distilled water
and mixed.
Preparation  of  0.2  M  sodium  hydroxide  solution:  Accurately  weighed  8  g  of  sodium
hydroxide pellets were dissolved in 1000 mL of distilled water and mixed.
Preparation of mobile phase:
Mobile phase is a mixed buffer of pH 3.2 (potassium dihydrogen orthophosphate) and organic
mixture (Acetonitrile and Methanol in the ratio of 90:10.) (V/V) in the ratio of 50:50 and filtered
through 0.45 µ and degassed.
Preparation of acid stage medium:
Dissolve 2.0 g of sodium chloride in 5.7 ml of HCl, and add water to makeup to 1000ml.
Preparation of standard solution (Acid stage):
Weigh  accurately  about  50  mg of  working  reference  standard  of  Eplerenone  exactly
weighed and transfer to 100 ml volumetric flask add 70 ml of diluents, sonicate to dissolve the
content and makeup to the mark with diluents. Transfer 2 ml of this solution, transfer into a 50
ml volumetric flask and dilute with buffer (pH1.2) and mix well. Filter the solution through0.45µ
membrane filter. 
Preparation of sample solution:
Weigh the tablets first and take as accurate as possible to formulation weight of the tablet
and transfer individually to six dissolution bowls having 500ml pH 1.2 buffer equilibrated to
37.0±0.5°C taking care to exclude air bubbles from the surface of the tablet and run apparatus.
After completion of 2 hrs with drawn 15ml of sample solution from each bowl and filter through
0.45µ filter. Samples will be taken for specified time points
Procedure: 
Separately  inject  100  µl  of  dissolution  media,  five  replicate  injections  of  standard
solution  and  single  injection  of  sample  solution  in  to  the  chromatograph,  record  the
chromatograms and measure the peak responses.
System suitability:
Chromatograph  the  standard  preparation  and  sample  preparation  record  the  peak
responses. The relative standard deviations for five replicate standard solution injections is not
more than 2.0%.
The tailing factor of peak should be not more than 2.0 and the theoretical plates of peak
should be not less than 2000.
Calculation:
Calculate the amount of drug substance released in pH 1.2 buffers in specified time intervals by
using this following formula.
At
As
×
Ws
100
×
2
50
×
2
50
×
500
1
×
P
Lableclaim∈ mg
Where,
At= The area of the Eplerenone peak in sample solution.
AS= The average area of the Eplerenone peak in sample standard solution.
Ws= Weight of the Eplerenone working standard taken in mg.
Wt= Weight of sample in mg.
P= Potency of the Eplerenone working standard.
Preparation of 0.5N Hydrochloric acid solution:
Mix 41.5 ml of Hydrochloric acid (35%) in 1000ml of water.
Preparation of standard solution (buffer stage):
Weigh  accurately  about  50  mg of  working  reference  standard  of  Eplerenone  exactly
weighed and transfer to 100 ml volumetric flask add 70 ml of diluents, sonicate to dissolve the
content and makeup to the mark with diluents. Transfer 2 ml of this solution, transfer into a 50
ml volumetric flask and dilute with buffer (pH 6.8) and mix well. Filter the solution through 0.45
µ membrane filter. 
Transfer 2 ml of this solution, transfer into a 50 ml volumetric flask and dilute with buffer
(pH 6.8) and mix well. Filter the solution through 0.45 µ membrane filter.
Transfer the 10 ml of above solution into a test tube contains 1.0 ml of 0.5 N HCl and
mix well. Filter the solution through 0.45µ nylon filter.
FTIR Studies
           FTIR studies were performed on drug and the optimized formulation using Shimadzu
FTIR (Shimadzu Corp., India). The samples were analyzed between wave numbers 4000 and 400
cm-1.
RESULTS AND DISCUSSION
Construction of Standard Graph of Eplerenone 
Table 14:Standard graph in pH 6.8 Phosphate buffer
Concentration (µg/ml) Peak Area
0 0
80 106795
90 119831
100 128817
110 141632
120 154964
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Fig 7:  Standard graph in pH 6.8 Phosphate buffer
Table 15: Standard graph in 0.1N HCl
Concentration (µg/ml) Peak Area
0 0
80 95968
90 109458
100 112856
110 138562
120 145268
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Fig 8: Standard graph in 0.1N HCl
Table 16: Preformulation Study results
S.N
o
Drug excipients blend
Ratio Condition: 40°C ± 2°C / 75% ± 5%
Initial 1
week
2
weeks
4
weeks
1 Eplerenone + sucrose
1:1
White  to  Off  white
crystalline powder
* * *
2 Eplerenone + hypromellose 1:1 White to Off white powder * * *
3 Eplerenone +Aqua coat ARC 1:1 White to Off white powder * * *
4 Eplerenone + Ethyl cellulose 1:1 White to Off white powder * * *
5 Eplerenone + Surelease 1:1 White to Off white powder * * *
6 Eplerenone + MCC 1:1 White to Off white powder * * *
7 Eplerenone + Mg.stearate. 1:1 White to Off white powder * * *
8 Eplerenone + Lubritab 1:1 White to Off white powder * * *
9 Eplerenone + Talc 1:1 White to Off white powder * * *
10 Eplerenone + Stearic acid 1:1 White to Off white powder * * *
11 Eplerenone + PEG 6000 1:1 White to Off white powder * * *
12 Eplerenone+  sucrose+
hypromellose+  Aqua  coat
ARC+  Ethyl  cellulose  +
Surelease+MCC+Mg.stearat
e+ Lubritab  + Talc+ Stearic
acid+ PEG 6000
1:1:1:1
:1:1:1:
1:1:1:1
:1
White  to  Off  white
crystalline powder
* * *
13 Sucrose+  hypromellose+
Aqua  coat  ARC+  Ethyl
cellulose  +  Surelease+
MCC+Mg.stearate+ Lubritab
+  Talc+  Stearic  acid+  PEG
6000
1:1:1:1
:1:1:1:
1:1:1:1
White  to  Off  white
crystalline powder
* * *
Note: * indicates there is no change in the physical appearance of the blend
Table 17: Assay results of the pellet formulations
S.No Trial no Assay (95%-105%)
1. Trial 3 102.3
2. Trial 4 99.6
3. Trial 5 100.6
4. Trial 6 102.5
5. Trial 7 99.6
6. Trial 8 101.0
7. Trial 9 101.4
8. Trial 10 100.8
9. Trial 11 101.1
Apparatus: Basket, Medium: pH 1.2 acid buffer for 2hrs & pH 6.8 phosphate buffer for 10 hrs, 
Volume: 900ml, RPM: 50
Table 18: Comparative Drug release profiles of the trial batches from Trial 3 to Trial 6
Trial 3 Trial 4 Trial 5 Trial 6
Dissolution: HPLC     
2hr (NMT 25%) 0.6 3.9 7.1 4
4hr  (20-40%) 16.5 20.1 23.6 20.2
6hr  (40-60%) 33.5 42.1 50.6 36.7
9hr  (60-80%) 55.2 62.1 68.9 60.4
12hr (NLT 85%) 67.8 80.0 92.1 73.5
Fig 9: Comparative Drug release profiles of the trial batches from Trial 3 to Trial 6
Table19: Comparative Drug release profiles of the trial batches from Trial 7 to Trial 11
Trial 7 Trial 8 Trial 9 Trial 10 Trial 11
Dissolution: HPLC      
2hr (NMT 25%) 2.2 12 2 5.8 9.4
4hr  (20-40%) 23.9 28.2 17.4 22.0 25.4
6hr  (40-60%) 46.1 55.1 35 44.0 52.9
9hr  (60-80%) 67 74.6 57.4 64.2 71.2
12hr (NLT 85%) 85.3 96 69.2 82.2 94.4
Fig 10: Comparative Drug release profiles of the trial batches from Trial 7 to Trial 11
Trial 1
In the first trial we have planned on the basis of literature to get the good drug layered pellets
using coating pan with powder dusting process. The prepared pellets found to be inconsistent in
shape and size. Since the pellets were not good to proceed further we have not performed coating
for this batch. 
Trial 2
In order to get uniform size and shaped spheres we have decided to reduce the concentration of
binder (both Sugar and HPMC) and compensated with the sugar powder addition as diluent in
this trial. Even though there is an improvement in the size and shape of the pellets it was not
found to be meeting our requirement as our target was to get the pellets with uniform shape and
size without any doublets or triplets in order to get the coating efficiency on sustained release
coating part. 
Trial 3
Hence it was further decided to reduce the concentration of binder (both sugar and HPMC) and
compensate with sugar powder as diluent. The prepared pellets were found to be good in shape
and size meeting our target. Further we have coated the prepared pellets using ethyl cellulose at
different concentration (10, 7.5, 5%) trial 3, 4, 5 respectively. Ethyl cellulose at 5% concentration
gave the dissolution profile meeting our target specification. Hence it was concluded that 5%
concentration  of  Ethyl  cellulose  would  be  the  ideal  concentration.
Trial 6, 7 & 8
Since our objective was to study the different cellulosic polymers effect  trial  6, 7 & 8 were
prepared using Surelease polymer at 10%, 7.5% & 5% respectively. Surelease at 7.5% level was
meeting the specification. However the release pattern was on the lower side. Surelease at 5%
level found to be satisfactorily meeting our targeted specification.
Trial 9, 10 & 11
Trial 9,10 & 11 were prepared using Aquacoat ARC at 10%, 7.5% & 5% concentration and based
on the results all three trails the batch with 7.5% coating was meeting the specification. However
the release pattern was on the lower side.  Trial  11 which contain 5% polymer showed good
release profile matching to the targeted specification. 
From the  above  studies  the  formulation  which  showed  the  release  profile  matching  to  the
specification (Trial 5, 7, 8, 10 & 11) has been taken for conducting alcohol resistant study. Since
concomitant consumption of alcoholic beverages along with the products might be expected to
have the potential to induce dose dumping.  Due to concerns of dose dumping from this drug
product when taken with alcohol, we have studied additional dissolution testing using various
concentrations of ethanol in the dissolution medium, as follows: 
Testing Conditions: 900 mL, 0.1 N HCl, apparatus I @ 50 rpm, with and without the alcohol 
Test 1: 12 units tested according to the proposed method (with 0.1 N HCl), with data collected 
every 15 minutes for a total of 2 hours. 
Table 20: Comparative Drug release profiles of the selected trial batches in 0.1N HCl without 
alcohol  
Without alcohol
 Trial 5 Trial 7 Trial 8 Trial 10 Trial 11
Time in min      
15min 0.9 0.6 1.4 0.7 1.1
30 min 1.8 1.1 2.9 1.4 2.3
45 min 2.7 1.7 4.4 2.2 3.1
60 min 3.6 2.2 5.9 2.7 4.3
75 min 4.5 2.7 7.4 3.5 5.3
90 min 5.5 3.3 8.9 4 6.5
105 min 6.4 3.8 10.4 4.8 7.8
120 min 7.3 4.3 11.8 6 8.9
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Fig 11: Comparative Drug release profiles of the selected trial batches in 0.1N HCl without 
alcohol
Test 2: 12 units analyzed by substituting 20% (v/v) of test medium with Alcohol USP, and data 
collection every 15 minutes for a total of 2 hours.
Table 21: Comparative Drug release profiles of the selected trial batches in 0.1N HCl with 20 % 
of alcohol 
With 20% alcohol
Trial 5 Trial 7 Trial 8 Trial 10 Trial 11
Time in min
15min 5.6 3.5 4.8 1.5 2.2
30 min 11.2 7.1 10.1 2.7 4.3
45 min 16.7 10.3 14.3 3.9 6.3
60 min 22.4 14.2 20.5 5.1 8.5
75 min 28.4 16.9 25.4 6.4 11.4
90 min 34.2 20.8 29.5 7.4 13.1
105 min 41.2 25.3 36.1 8.8 15.6
120 min 45.3 28.2 41.1 10 18
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Fig 12: Comparative Drug release profiles of the selected trial batches in 0.1N HCl with 20 % of 
alcohol 
 Test 3: 12 units analyzed by substituting 40% (v/v) of test medium with Alcohol USP, and data 
collection every 15 minutes for a total of 2 hours.
Table 22: Comparative Drug release profiles of the selected trial batches in 0.1N HCl with 40 % 
of alcohol 
With 40% alcohol
 Trial 5 Trial 7 Trial 8 Trial 10 Trial 11
Time in min      
15min 7.4 4.4 5.6 1.7 2.1
30 min 15.1 8.5 11.3 3 4.5
45 min 22.1 12.2 16.5 4.1 6.4
60 min 31.2 17.8 23.2 5.7 8.8
75 min 38.5 21.4 28.5 6.4 11.5
90 min 45.6 25.3 33.5 7.8 14
105 min 52.3 30.4 40.3 10.2 16.3
120 min 60.2 35.4 45.3 12 21.3
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Fig 13: Comparative Drug release profiles of the selected trial batches in 0.1N HCl with 40 % of 
alcohol
From the above study formulation 10 found to be more ideal pellets formulation for next study. 
Hence the pellets prepared according to trial 10 were further compressed in to tablets using 
different concentration of cushioning agent Lubritab. The prepared tablet formulations were 
analyzed for content uniformity and the formulation F4 had shown good content uniformity with 
the L1 value less than 15 (n=10). 
Table 23
s.no Content uniformity L1 value Assay Hardness Disintegration
F1 43 97.7 40-50 N 15-20 sec
F2 25 105.6 40-50 N 5 min
F3 19 102.3 40-50 N 7 min
F4 7.9 100.8 40-50 N 10 min
Table 24: Dissolution profile of the tablet formulation i.e., F4
F4
Dissolution: HPLC  
0 0
2hr (NMT 25%) 8.5
4hr  (20-40%) 23.8
6hr  (40-60%) 54.8
9hr  (60-80%) 75.6
12hr (NLT 85%) 92.4
FTIR Studies
           FTIR studies were performed on drug and the optimized formulation using Shimadzu
FTIR (Shimadzu Corp., India). The samples were analyzed between wavenumbers 4000 and 400
cm-1.
Fig 14 : Eplerenone API FTIR graph 
Fig 15 :Eplerenone optimized formulation (F4) FTIR graph 
Fig 16: Eplerenone formulation Placebo FTIR graph 
Eplerenone has an ester carbonyl stretch of approximately 1739 cm−1 methyl ethyl ketone solvate
have the corresponding stretch at  approximately 1724 and 1722 cm−1,  respectively.  The ester
carbonyl stretch occurs at  approximately 1727 cm−1 the stretch of the ester of the conjugated
ketone in the A-steroid ring shifts from approximately 1664-1667 cm−1. The functional group
responsible peaks were appearing in the API, Formulation FTIR graphs, so that we concluded
that there is no change in the activity of the Eplerenone API.    
Kinetic study the Final formulation 
Kinetic profiles were calculated for the final formulation and the data presented below,  
Zero Higuchi Peppas n value First
Hixson 
Crowell
0.938991 0.859135 0.97358 0.599 0.988 0.987
The above data shows that the formulation is following the first order kinetic and erosion 
mechanism with non-Fickian (Anomalous) release
Graphical representation of the kinetic study results
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Fig 17: Zero order release kinetics of the optimized formulation 
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Fig 18 : First order release kinetics of the optimized formulation 
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Fig 19: Hixson crowell model release kinetics of the optimized formulation 
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Fig 20: Higuchi model release kinetics of the optimized formulation 
Summary and conclusion
Eplerenone is a highly selective aldosterone receptor antagonist (SARA) to effectively block
aldosterone at  receptor sites  in  body tissues  (Spertus  J.A.et  al.,  2002).  Aldosterone plays  an
important role in chronic heart failure, even when other rennin–angiotensin–aldosterone system
(RAAS)-inhibiting agents are used (Stier C.T, 2002, Staessen S.,1981). Eplerenone is used for
treatment of hypertension and heart failure. Eplerenone is a steroid nucleus- based antimineral
corticoid that is chemically and enzymatically interconvertible to an open lactone ring form. It is
rapidly  and  nearly  completely  absorbed  from the  gastrointestinal  tract  (GIT)  following  oral
ingestion, showing 69% bioavailability. Detectable plasma levels occur within one-half hour and
peak plasma levels occur in about 1-2 hours. A plasma half-life is 4 hours.  In the treatment of
hypertension the usual initial dosage is 25 mg once daily, whether used alone or added to diuretic
therapy.  Dosage may be increased or  decreased depending on  heart  rate and  blood pressure
response. The usual total maintenance dosage is 50-100 mg per day.
Although conventional tablets of Epelerenone are available in the market commercially, no study
has been done so far for preparing the Epelerenone sustained-release tablets. To improve the oral
bioavailability and to reduce the dose dependent toxicity there is a need for the development of
sustained-release formulations (Gregory et al., 2004; Mandana et al., 2000)
The intention of  present  study was to adopt  a  novel  approach in designing and characterize
twice-daily sustained-release (MUPS) tablets of Eplerenone, using Cellulose polymers as release
modifiers in the form of matrix layer spherical particles in the tablets. Multi unit particles in the
tablets containing cellulose polymers like ethyl cellulose, Surelease and Aqua coat ARC, were
prepared by drug layering and coating those particles in FBC with suspension layering technique
using Hypromellose as a binder solution and the tabletting process was optimized for formation
of uniform tablets in all respects.
In this study Eplerenone pellets are prepared using powder layering technique and coated using
Fluid bed processor for the strength of 50% to achieve the final tablet formulation of 70mg dose.
Eleven  formulations  of  sustained  release  pellets  are  prepared  by  using  different  cellulosic
polymers varying in their concentration (10%, 7.5% & 5%). Ethyl cellulose at 5% level gave the
dissolution profile meeting the requirement. Further Surelease/ Aqua coat at 7.5% concentration
gave the dissolution profile matching to the specification with the release at lower side of the
specification. At 5% level both Surelease and Aqua coat ARC gave acceptable dissolution profile
matching to the specification. Since concomitant consumption of alcoholic beverages along with
the products might be expected to have the potential to induce dose dumping. Due to concerns of
dose  dumping from this  drug  product  when  taken  with  alcohol,  we  have  studied  additional
dissolution testing using various concentrations of ethanol in the dissolution medium for the
batches which showed match in the dissolution profile. Based on the study it is further concluded
that  the  pellets  prepared  using  Aqua  coat  ARC at  7.5% concentration  (Trial  10)  was  more
identical  and  not  showed any significant  effect  in  the  presence  of  alcohol.  Further  the final
formulation trail 10 compressed in to tablets for 70mg dose and from the study it is concluded
that  the  concentration  of  10mg  Lubritab  found  to  be  meeting  in  all  respect.  The  prepared
formulation studied for stability and the results were found to be satisfactory after one month
accelerated condition (40ºC/ 75% RH). 
The  Optimized  formulation  shall  be  utilized  for  the  development  and  other  studies  like
bioequivalence for the successful launching of this product.
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